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Besides the complexity of protein samples, probably the greatest challenge presently 
facing comprehensive proteome analysis is related to the large variation of protein relative 
abundances (>6 orders of magnitude), having potential biological significance in 
mammalian systems. To achieve comprehensive proteome analysis including the 
identification of low abundance proteins, this project aims to develop and demonstrate a 
capillary isotachophoresis (CITP)-based proteome platform, capable of providing selective 
analyte enrichment and extremely high resolving power toward complex protein mixtures. 
In contrast to universally enriching all proteins by a similar degree, the result of the CITP 
stacking process is that major components may be diluted, but trace compounds are 
concentrated.  
By employing combined CITP/nano-reversed phase liquid chromatography (nano-RPLC) 
separations, a total of 6,112 fully tryptic peptides are sequenced by electrospray ionization 
mass spectrometry (ESI-MS), leading to the identification of 1,479 distinct human 
  
SwissProt protein entries from a single proteome sample of whole unstimulated human 
saliva. By comparing with capillary isoelectric focusing as another electrokinetics-based 
stacking approach, CITP not only offers a broad field of application, but also is less prone 
to protein/peptide precipitation during the analysis. 
 The CITP-based proteome platform is further employed for the analysis of protein 
expression within synaptic mitochondria isolated from mouse brain. The ultrahigh 
resolving power of CITP separation is evidenced by the large number of distinct peptide 
identifications measured from each CITP fraction together with the low peptide fraction 
overlapping among identified peptides. Furthermore, the collective proteome datasets 
yield the identification of 2,191 distinct mitochondrial protein entries, corresponding to 
76% coverage of the MitoP2-database reference set. 
Comparisons among CITP and multidimensional liquid chromatography techniques are 
conducted using a single processed protein digest from brain cancer stem cells, identical 
second dimension separation (nano-RPLC) and ESI-MS conditions, and consistent search 
parameters and cutoff established by the target-decoy determined false discovery rate. 
Besides achieving superior overall proteome performance in total peptide, distinct peptide, 
and distinct protein identifications, analytical reproducibility of the CITP proteome 
platform is determined by a Pearson R2 value of 0.98 and a coefficient of variation of 15% 
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1.1  Introduction 
Mass spectrometry (MS) employing electrospray ionization (ESI) and matrix-assisted 
laser desorption/ionization (MALDI) interfaces has evolved to become an essential 
tool for protein identification and sequencing. The vast number of proteins present in 
the proteome of a typical organism, tissue, and organ, however, requires that 
separations be performed on the mixture prior to introduction into a mass 
spectrometer. Capillary electrophoresis is based on a family of electrokinetically 
resolving mechanisms which are performed in narrow-bore capillaries under the 
influence of an electric field. Besides two-dimensional polyacrylamide gel 
electrophoresis (2-D PAGE) and liquid chromatography, capillary electrophoretic 
separations are attractive and promising alternatives due to their excellent efficiency, 
high resolving power, and ability to handle small cell populations and limited tissue 







1.2  Single Dimension Capillary Electrophoretic Separation   
Capillary zone electrophoresis (CZE) resolves proteins and peptides based on their 
differences in electrophoretic mobility which is a function of the charge-to-size ratio. 
Due to its high throughput and excellent resolving power, the coupling of CZE with 
ESI-MS is therefore a particularly attractive approach for the discovery of biomarkers 
in human urine and serum. Peptides from healthy volunteers’ urine were prepared and 
concentrated using a combination of anion-exchange chromatography and 
lyophilization and then compared with those from kidney disease patients’ dialysate 1. 
The application of CZE-ESI-MS has been shown to locate more potential kidney 
disease biomarkers 2, 3 than those obtained from surface-enhanced laser 
desorption/ionization (SELDI)-MS 4. Additionally, CZE-ESI-MS has been employed 
to obtain peptide patterns from urine samples of urothelial cancer patients and healthy 
volunteers 5.     
One characteristic inherent to CZE is the small sample volume that can be successfully 
applied to obtain a high-resolution analysis. As a good portion of the important 
proteins/peptides contained in a proteomic sample may be present at low levels, it 
becomes important to combine sample concentration/preparation in-line with the 
subsequent electrophoretic separations while avoiding analyte loss or dilution due to 
manual handling and transfer procedures. Thus, transient capillary isotachophoresis (CITP) 
was employed for on-capillary preconcentration of serum peptides prior to CZE separation 
6. CITP, unlike most separation modes in capillary electrophoresis, employs a 
discontinuous electrolyte system. The stacking and separation of peptides and proteins 




mobility) electrolytes under the influence of an applied electric field. The application of 
transient CITP/CZE separations significantly impacts the analysis of low abundance 
peptides by effectively enhancing the dynamic range and detection sensitivity of MS as 
demonstrated by An and co-workers 7. 
 
1.3  Capillary Electrophoresis-Based Multidimensional Separations 
In addition to protein complexity, probably the greatest challenge facing 
comprehensive proteome analysis is related to the large variation of relative protein 
abundance (greater than 6 orders or magnitude) in human serum/plasma and urine 
samples. The use of only a single electrophoretic separation such as CZE prior to MS 
detection greatly limits the ability for mining deeper into the clinical proteome. 
Assuming the separation techniques used in the two dimensions are orthogonal, i.e., 
the two separation techniques are based on different physicochemical properties of 
proteins/peptides, the peak capacity of 2-D separations is the product of the peak 
capacities of individual one-dimensional approaches. Thus, various capillary 
electrophoresis-based 2-D separation schemes have been developed in an effort to 
improve the overall peak capacity and increase the number of detected peptides and 
proteins identified due to better use of the MS dynamic range and reduced 
discrimination during ionization.   
 
1.3.1  Capillary liquid chromatography-capillary electrophoresis 
A 2-D reversed-phase liquid chromatography (RPLC)-CZE separation platform has been 




serum sample was depleted of high-abundance proteins, digested with trypsin, and then 
separated by RPLC and collected into 96 fractions. These fractions, collected off-line from 
the RPLC separation, were subjected to sequential CZE separations through a sheathless 
ESI interface that was integrated on the separation capillary. A key feature of this work is 
the employment of RPLC in lieu of ion exchange fractionation as the first separation 
dimension, where there is a large degree of overlap. The CZE-MS results demonstrated 
less than 15% overlap between neighboring RPLC fractions, leading to a more sensitive 
proteome analysis. 
Instead of resolving complex protein digests, intact proteins from liver cancer tissue have 
been separated using RPLC followed by array-based capillary isoelectric focusing (CIEF) 
equipped with whole column image detection 9. In addition to the laser-induced 
fluorescence detection (LIFD), the CIEF protein fractions could be subsequently deposited 
on to MALDI-targets. On-target tryptic digestion of collected CIEF fractions was 
performed to generate peptide mass fingerprint for the identification of proteins in rat liver 
tissue extracts 10.    
 
1.3.2  Capillary electrophoresis-capillary electrophoresis 
Michaels and co-workers 11 detailed a 2-D electrokinetic separation system by on-line 
combination of micellar electrokinetic chromatography (MEKC) with CZE for resolving 
complex protein mixtures based on their differences in hydrophobicity and charge-to-size 
ratio, respectively. Protein fractions from the first dimension MEKC separation were 
transferred to a second capillary through an injection interface, where CZE was performed 
and followed by LIFD. Hu et al. 12 further combined capillary size-sieving electrophoresis 




study of protein expression in single mammalian cells. After a 6-min-long size-based 
separation, over 100 transfers of fractions from the first capillary were introduced into a 
second capillary for further separation by MEKC over an approximately 3.5-hr-long 
period.    
 
1.3.3  Capillary electrophoresis-liquid chromatography 
On-line combination of CIEF with capillary electrochromatography (CEC) via a 
nanoinjector valve has been reported by Zheng and El Rassi 13 for the analysis of 
albumin-depleted human serum. The serum proteins were systematically resolved by 
exploiting their differences in isoelectric point (pI) and hydrophobicity, and detected 
using UV absorbance.  The key challenge associated with using CEC to perform 
peptide and protein separations is the requirement of charged surfaces that generate 
reproducible electroosmotic flow as an electrokinetically-driven pump for the 
delivery of the mobile phase.  
Since the sizes of human tissue biopsies are becoming significantly smaller due to the 
advent of minimally-invasive methods and early detection and treatment of lesions, a more 
effective discovery-based proteome technology is critically needed to enable global 
studies of protein profiles that will have diagnostic and therapeutic relevance. A CIEF-
based clinical proteomics platform, which combines CIEF with nano-RPLC (Figure 1-1), 
has recently been developed to achieve comprehensive and ultrasensitive analysis of 
minute protein amounts extracted from small cell populations and limited tissue samples 
14-17. The key to performing sensitive clinical proteome analysis is to attain high analyte 
concentrations in small peak volumes prior to MS. The application of electrokinetic 




separations greatly enhance the dynamic range and detection sensitivity of MS 
measurements. Furthermore, the microcolumn format of CIEF and nano-RPLC provides 
the amenability to automation and seamless coupling with ESI-MS in an integrated 
platform while avoiding potential sample loss and analyte dilution. 
Combined CIEF/nano-RPLC separations have been employed for the analysis of 
protein profiles within small and selected tumor cell populations obtained from the a 
glioblastoma multiforme (GBM) tissue specimen 14. By using ESI-quadrupole time-
of-flight-MS for the analysis of peptides eluted from nano-RPLC (Figure 1-2), a total 
of 6,866 fully tryptic peptides have been detected, leading to the identification of 
1,820 distinct proteins each corresponding to a unique human International Protein 
Index database entry.  
These identifications were generated from a total of 18,843 tandem mass spectra from 
3 runs of a single GBM tissue sample, with each run consuming only 10 µg of total 
protein. These identifications were based on high mass accuracy and high confidence 
hits to fully tryptic peptides. Furthermore, a variety of protein classes, including 
structural proteins, metabolic enzymes, receptors, and proteins involved in 
transcription, translation, and post-translational modification of gene products, were 














































Figure 1-1 Schematic of on-line integration of CIEF with nano-RPLC as a concentrating 
and multidimensional protein/peptide separation platform. Solid and dashed 
lines represent the flow paths for the loading of CIEF fractions and the 








Figure 1-2 Base peak chromatograms of a representative CIEF/nano-RPLC 
multidimensional separation of tryptic peptide digest prepared from GBM 
tissue sample. Each number represents the sequence of CIEF fractions further 






In addition to the analysis of soluble proteins within tumor cells, the tissue proteome 
capabilities of combined CIEF/nano-RPLC separations have been further expanded for the 
identification of membrane proteins extracted from cell pellets using SDS detergent. 
Epithelial ovarian carcinoma tissue specimens containing the serous cell type were 
processed and employed for the membrane proteome analysis 17. The peptide and protein 
false discovery rates (FDRs), and the numbers of total peptides, distinct peptides, and 
protein identifications were plotted as functions of the E-value using the Open Mass 
Spectrometry Search Algorithm (OMSSA) 19 (Figure 1-3). An E-value threshold of 0.05, 
corresponding to 1% FDR of total peptide identifications, was chosen as a cutoff and 
resulted in the identification of 18,861 distinct peptides together with 3,303 non-redundant 
proteins from the SwissProt human database. This cutoff led to a protein false positive rate 
of 6.8% as indicated by the detection of peptides from 112 distinct reversed protein 
sequences in the decoy section of the search database.  
Among 12,484 protein entries in the SwissProt human database, a total of 3,514 proteins 
are predicted to contain at least one or more transmembrane domains using TMHMM 
(www.cbs.dtu.dk/services/TMHMM-2.0/). Out of these membrane protein candidates, 
773 proteins were identified from the pellets of targeted ovarian tumor cells, 
corresponding to 22% membrane proteome coverage. Of the 773 proteins, only 291 
proteins or 37% were also found in the soluble protein fraction of ovarian tissues using the 
urea solubilization protocol. Moreover, there were only 69 additional membrane proteins 
identified in the soluble protein fraction, affirming the utility of SDS extraction coupled 











Figure 1-3 Plots of the false positive rates and the numbers of total peptide,   distinct 
peptide, and distinct protein identifications versus the E-value obtained 
from the search of the peak list files against a decoyed SwissProt human 










Because of the long history of the use of formalin as the standard fixative for tissue 
processing in histopathology, there are a large number of archival formalin-fixed and 
paraffin-embedded (FFPE) tissue banks worldwide. However, the high degree of 
covalently cross-linked proteins in FFPE tissues hinders efficient extraction of proteins 
from tissue sections and prevents subsequent proteomic efforts from retrieving 
information sequestered in archival tissues. By coupling with the antigen retrieval (AR) 
technique originally developed for immunohistochemistry 20, multidimensional 
CIEF/nano-RPLC separations have been employed to examine protein profiles extracted 
from a whole FFPE tissue section of human renal carcinoma 21. A total of 3,336 distinct 
peptides were identified with a false positive rate of 1% from the tissue section treated 
with the heat-induced AR approach, leading to the identification of 1,830 distinct proteins. 
The mechanism of AR technique appears to involve a re-naturation of the structure of 
fixed proteins through a series of conformational changes, including the possible breaking 
(hydrolysis) of formalin-induced cross-linkages, the entire process being driven by 
thermal energy from the heat source.  
Instead of examining whole tissue sections, minute proteins procured from GBM 
FFPE tissues have been processed, profiled, and compared with those extracted from 
fresh frozen tissues of the same, matched patient 22. The entire content of focused 
peptides in the CIEF capillary was split into 19 individual fractions (Figure 1-4) 
which were further resolved by nano-RPLC and identified using nano-ESI-linear ion 
trap-MS/MS. An E-value threshold of 0.17, corresponding to 1% false positive of 




distinct peptides were identified, leading to the identification of 2,845 non-redundant 
proteins from the SwissProt human database. This identity threshold also resulted in a 
protein false positive rate of 7.5% as indicated by the detection of peptides from 107 
distinct reversed protein sequences in the decoy section of the search database. 
Combined CIEF/nano-RPLC separations were also employed in the analysis of protein 
digests obtained from the soluble and cell pellet fractions of patient-matched fresh frozen 
GBM tissue. A total of 2,856 and 3,227 proteins were identified from the soluble and 
pellet fractions, respectively. By combining the proteome results obtained from the soluble 
and pellet fractions, the collective analysis yielded the identification of 3,902 non-
redundant proteins with an average of 6.2 peptides per protein. 
Comparing the proteome results obtained from the fresh frozen and FFPE GBM tissues 
(Figure 1-5), most proteins identified from the FFPE slide were also detected in the 
corresponding fresh frozen section. Only 243 proteins, representing 8.5% of total protein 
identifications, were unique to the FFPE tissue. Among proteins identified from the FFPE 
tissue, 2,370 proteins or 83% of the total protein identifications, overlapped with those 















Figure 1-4 Overlaid plots containing the CIEF-UV trace monitored at 280 nm, the 
number of distinct peptides identified in each of the CIEF fractions, and 



















Figure 1-5 The overlap in the proteins identified from fresh frozen (the soluble and 
pellet fractions) and FFPE GBM tissue specimens of the same patient 
using combined CIEF/nano-RPLC separations coupled with nano-ESI-






1.4  Project Description 
Predictions of disease behavior and therapeutic response have been complicated by the 
great complexity of the human genome and the heterogeneity among different cell types. 
To address the issue of cell heterogeneity, several microdissection techniques 23-25 have 
been developed to provide a rapid and straightforward method for isolating selected 
subpopulations of diseased cells for subsequent genetic and proteomic analyses. 
Developments in capillary electrophoresis-based multidimensional separations are 
particularly important for their roles in achieving ultrasensitive and comprehensive 
analysis of minute proteins extracted from isolated cell populations. 
Besides the complexity of protein samples, probably the greatest challenge presently 
facing comprehensive proteome analysis is related to the large variation of protein relative 
abundances (>6 orders of magnitude), having potential biological significance in 
mammalian systems. One obvious approach to increase the detection capability of low 
abundant proteins is to significantly raise the sample loading along with many additional 
protein/peptide fractionation and separation procedures, and therefore may be impractical 
for proteomic studies of small cell populations or limited tissue samples. To achieve 
comprehensive proteome analysis including the identification of low abundance proteins, 
my research efforts therefore focus on the development of transient CITP/CZE-based 
multidimensional separation technique and the demonstration of its unique bioanalytical 
capabilities toward the analysis of complex mammalian proteomes.  
While CITP has been widely used for analyte preconcentration prior to electrophoretic 
separation, the application of CITP to selectively enrich trace amounts of proteins in 




development. CITP, unlike most separation modes in CE, employs a discontinuous 
electrolyte system. A CITP capillary is initially filled with a leading electrolyte such as 
ammonium acetate with a mobility greater than any of the sample components. Following 
sample injection, the inlet end of the capillary is placed in a terminating electrolyte such as 
acetic acid. The stacking and separation of analytes occurred in the boundary region 
between the leading and terminating electrolytes by applying an electric voltage (Figure 1-
6). 
Under the influence of constant current across the entire capillary, the sections containing 
the high-mobility leading electrolyte and the low-mobility terminating electrolyte would 
therefore experience lower and higher electric fields, respectively. The analyte ions in the 
sample zone initially migrating at fast speed under the influence of high electric field are 
slowed down and stacked at the interface of the sample and leading electrolyte sections. 
Stable boundaries formed between analytes and are based on their individual mobilities. In 
CITP, all bands move at the same velocity as the bands are focused. The individual band 
velocities are self-normalizing because the band containing the highly mobile analyte ions 
had high conductivity and, as a result, exhibited a lower voltage drop across the band. 
Stacking is also a consequence of velocity normalization. For example, if a band diffuses 
into a neighboring zone, it will either speed up or slow down, based on the field strength 
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Figure 1-6  Schematic view of the CITP-based electrokinetic stacking mechanism.  C: 
concentration; E: applied electric field strength; LE: leading electrolyte; 





In contrast to universally enriching all proteins by a similar degree, the result of the CITP 
stacking process is that major components may be diluted, but trace compounds are 
concentrated. Such selective enhancement toward low abundance proteins can drastically 
reduce the range of relative protein abundances in complex proteomes, and greatly 
improve proteome coverage using the CITP-based multidimensional protein/peptide 
separation technology.  
Chapter 2 applied a multidimensional CITP/CZE-nano-RPLC separation platform coupled 
with ESI-tandem MS for the characterization of whole unstimulated human saliva. 
Besides initial evaluation of the CITP proteome technology, the foundation for saliva-
based diagnostics is the development of a complete catalog of secreted proteins detectable 
in saliva. Besides protein complexity, the greatest challenge facing comprehensive 
analysis of saliva samples is related to the large variation of protein relative abundances 
including the presence of high abundance proteins such as amylases, mucins, praline rich 
proteins (PRPs), and secretory IgA complex.  
A total of 6,112 fully tryptic peptides were sequenced at a 1% FDR, leading to the 
identification of 1,479 distinct human SwissProt protein entries. By comparing with 
CIEF as another electrokinetics-based stacking approach, CITP/CZE not only offered 
a broad field of application, but also was less prone to protein/peptide precipitation 
during the analysis. The ultrahigh resolving power of CITP/CZE was evidenced by 
the large number of distinct peptide identifications measured from each CITP fraction 
together with the low peptide fraction overlapping among identified peptides. 
Furthermore, when evaluating the protein sequence coverage by the number of 




technology similarly achieved the superior performance with 674 proteins (46%) 
having 3 or more distinct peptides, 288 (19%) having 2 distinct peptides, and 517 
(35%) having a single distinct peptide. 
In addition to their biological and medical significance, mitochondria are ideal targets 
for global proteome analysis because they have a manageable level of complexity as a 
consequence of their apparent prokaryotic ancestry. Still, proteins cataloged from 
reported proteomic studies comprise only small part of the estimated total human 
mitochondrial proteins. A CITP-based multidimensional separation platform, capable 
of providing selective analyte enrichment and high resolving power toward complex 
protein/peptide mixtures, was therefore employed in Chapter 3 for the analysis of 
synaptic mitochondria isolated from the brains of mice.       
A total of 1,795 distinct mouse SwissProt protein entries were identified from synaptic 
mitochondria isolated from mouse brain. The ultrahigh resolving power of CITP/CZE was 
evidenced by the large number of distinct peptide identifications measured from each 
CITP fraction together with the low peptide fraction overlapping among identified 
peptides. The degree of peptide overlapping among CITP fractions was even lower than 
that achieved using combined CIEF/nano-RPLC separations for the analysis of the same 
mitochondrial sample. When evaluating the protein sequence coverage by the number of 
distinct peptides mapping to each mitochondrial protein identification, CITP/CZE 
similarly achieved superior performance with 1,041 proteins (58%) having 3 or more 





The reproducibility of protein identifications was found to be around 86% by 
comparing proteins identified from repeated runs of the same mitochondrial sample. 
The analysis of the mouse mitochondrial proteome by two CITP/CZE runs resulted in 
the detection of 2,095 distinct mouse SwissProt protein entries, corresponding to 59% 
coverage of the updated Maestro mitochondrial reference set. The collective analysis 
from combined CITP/CZE and CIEF-based proteomic studies yielded the 
identification of 2,191 distinct mitochondrial protein entries, corresponding to 76% 
coverage of the MitoP2-database reference set. 
Comparisons among shotgun proteome technologies, including CITP-based 
multidimensional separations and multidimensional liquid chromatography system, 
were performed in Chapter 4 regarding their abilities to address the challenges of 
protein complexity and relative abundance inherent in GBM derived cancer stem cells. 
Comparisons were conducted using a single processed protein digest with equal 
sample loading, identical second dimension separation (nano-RPLC) and MS 
conditions, and consistent search parameters and cutoff established by the target-
decoy determined FDR. Besides achieving superior overall proteome performance in 
total peptide, distinct peptide, and distinct protein identifications, analytical 
reproducibility of the CITP proteome platform coupled with the spectral counting 
approach was determined by a Pearson R2 value of 0.98 and a coefficient of variation 
(CV) of 15% across all proteins quantified. In contrast, extensive fraction overlapping 
in strong cation exchange greatly limited the ability of multidimensional liquid 
chromatography separations for mining deeper into the tissue proteome as evidenced 




Chapter 2: Comparison of Electrokinetics-Based 
Multidimensional Separations Coupled with Electrospray 
Ionization-Tandem Mass Spectrometry for Characterization 
of Human Salivary Proteins 
Reproduced with permission from Fang, X., Yang, L., Wang, W., Song, T., DeVoe, D. L., 
Lee, C. S., Balgley, B. M., Anal. Chem.(2007), 79 (15), 5785 -5792. 
 Copyright 2007 American Chemical Society 
 
2.1  Introduction 
Whole saliva is derived predominantly from three paired major salivary glands, 
accounting for about 90% of fluid production, as well as from minor salivary glands. 
Besides playing a role in digestion, lubrication, and formation of a pellicle that 
protects teeth and mucosal surfaces, salivary components are important determinants 
of oral health and essential in regulating the oral ecology26. Alterations in the 
composition of the oral flora and/or immune dysfunction are often linked to common 
oral diseases. In turn, changes in salivary composition correlate with disease 
susceptibility and/or progression. Human saliva is therefore a potential source of 
novel diagnostic markers and therapeutic targets27-33.  
There has been growing interest in identifying “salivary biomarkers” as a means of 
monitoring general health and for the early diagnosis of diseases, such as bacterial 




affect the function of salivary glands, e.g. Sjogren’s syndrome, alcoholic cirrhosis, 
cystic fibrosis, diabetes mellitus, diseases of the adrenal cortex, cardiovascular 
diseases, and dental caries31, 34-36. For example, differences in proteolytic processing 
of basic proline rich proteins (PRPs) from the human parotid gland have been 
associated with caries37. Saliva samples obtained from oral cancer patients have been 
profiled and compared with those from healthy control subjects38. Studying the 
expression of specific salivary proteins has demonstrated that the family of defensins 
exhibits antibiotic, antifungal, and antiviral properties39-43. Additionally, detailed 
knowledge of salivary composition will be helpful in the construction of artificial 
salivas for use by patients with xerostomia and salivary hypofunction. These 
conditions are commonly associated with head and neck radiotherapy, Sjogren’s 
syndrome, and the use of antidepressants44-46. In fact, the efficacy and safety of 
including antimicrobial proteins in artificial salivas have recently been under 
evaluation47.  
Several research groups have employed the two-dimensional polyacrylamide gel 
electrophoresis-mass spectrometry (2-D PAGE-MS) technique for the analysis of whole 
saliva and parotid gland secretions and have identified less than 200 proteins, which only 
represents a small portion of the salivary proteome48-53. In addition to the separation of 
intact proteins using 2-D PAGE, Yates and co-workers54, 55 developed and demonstrated 
the use of shotgun identification of protein mixtures by proteolytic digestion followed with 
multidimensional liquid chromatography and tandem MS to separate and fragment the 
resulting peptides. A total of 102 and 266 proteins were identified from tryptic digests of 




respectively. Instead of using strong cation exchange chromatography as the first 
separation dimension, free flow electrophoresis has been coupled with reversed-phase 
liquid chromatography (RPLC) for achieving multidimensional peptide separations and 
leading to the identification of 437 salivary proteins57. The overlap among these cataloged 
proteins50, 56, 57 was relatively small and included most of the common proteins present in 
high abundance and associated with housekeeping functions.  
The greatest bioanalytical challenge facing comprehensive proteome analysis of saliva 
samples is related to the large variation of protein relative abundances. Similar to other 
body fluids such as serum and plasma, the large variation of protein relative abundances 
together with the complexity of the saliva proteome continuously challenges the 
development of proteome technologies from sample processing to separation and MS 
detection58. One obvious approach to enhance the proteome coverage and the detection 
capability of low abundance proteins is to significantly raise the required amounts of 
protein along with many additional sample preparation/fractionation/separation processes 
59-62, including the depletion of high abundance proteins such as albumins in serum/plasma 
samples. For example, N-linked glycoproteins in human saliva were captured and 
enriched using the hydrazide coupling and release approach which functions as a pre-
fractionation technique for handling highly complex biofluids63. A total of 84 N-
glycosylated peptides were identified and associated with 45 unique N-glycoproteins, 
including 16 glycoproteins that have not been reported previously in saliva.      
The high resolving power of capillary bioelectric focusing (CIEF) as the first 
dimension in combined CIEF/nano-RPLC separations14, 17, 18 was evidenced by the 




peptides present in more than one CIEF fraction was only around 20-25%14, 17, 
significantly less than 40-80% obtained from multidimensional liquid 
chromatography system using strong cation exchange coupled with RPLC55, 64. By 
employing a CIEF-based multidimensional separation platform coupled with 
electrospray ionization (ESI)-tandem MS, a total of 3,642 fully tryptic peptides were 
sequenced at a 1% false discovery rate (FDR), leading to the identification of 1,165 
distinct SwissProt protein entries from a single human saliva sample65.  
Instead of using CIEF as the first dimension, a capillary isotachophoresis (CITP)-
based multidimensional separation platform, capable of providing selective analyte 
enrichment and high resolving power toward complex protein/peptide mixtures, is 
employed in this study to further address the challenges of protein complexity and 
protein relative abundance inherent in human saliva proteome. In contrast to 
universally enriching all analytes by a similar degree, the result of the CITP stacking 
process is that major components may be diluted, but trace compounds are 
concentrated7, 66-68. As demonstrated in our recent studies7, such selective 
enhancement toward low abundance proteins can drastically reduce the range of 
relative protein abundances and greatly improve the sequence analysis of low 
abundance proteins in complex proteomes. Furthermore, CITP offers the benefits of 
speed and straightforward manipulation/switching between the stacking and 






2.2  Experimental Section 
 
2.2.1  Material and Reagents 
Fused-silica capillaries (50 µm i.d./375 µm o.d. and 100 µm i.d./375 µm o.d.) were 
acquired from Polymicro Technologies (Phoenix, AZ). Acetic acid, dithiothreitol (DTT), 
iodoacetamide (IAM), and protease inhibitors were obtained from Sigma (St. Louis, MO). 
Acetonitrile, hydroxypropyl cellulose (average MW 100,000), 
tris(hydroxymethyl)aminomethane (Tris), and urea were purchased from Fisher Scientific 
(Pittsburgh, PA). Pharmalyte 3-10 was acquired from Amersham Pharmacia Biotech 
(Uppsala, Sweden). Sequencing grade trypsin was obtained from Promega (Madison, WI). 
All solutions were prepared using water purified by a Nanopure II system (Dubuque, IA) 
and further filtered with a 0.22 µm membrane (Millipore, Billerica, MA). 
 
2.2.2  Saliva Sample Collection and Preparation 
Whole unstimulated saliva was collected from a healthy male volunteer. 1 mL of saliva 
was placed in a tube containing a mixture of protease inhibitors (1 µg aprotinin, 1 µg 
pepstatin A, and 1 µg leupeptin) and centrifuged at 20,000 g for 30 min. The supernatant 
was collected and placed in a dialysis cup (Pierce, Rockford, IL) and dialyzed overnight at 
4 °C against 100 mM Tris at pH 8.2. Urea and DTT were added to the sample with final 
concentrations of 8 M and 1 mg/mL, respectively, and incubated at 37 °C for 2 hr under 
nitrogen. IAM was added to a concentration of 2 mg/mL and kept at room temperature for 
1 hr in the dark. Trypsin was added at a 1:20 (w/w) enzyme to substrate ratio and 




column (Michrom Bioresources, Auburn, CA) and lyophilized to dryness using a  
SpeedVac (Thermo Savant, San Jose, CA), and then stored at -80 °C. 
 
2.2.3  Transient CITP/CZE-Based Multidimensional Separations  
The CITP apparatus was constructed in-house using a CZE 1000R high-voltage 
power supply (Spellman High-Voltage Electronics, Plainview, NY). A 80-cm long 
CITP capillary (100 µm i.d./365 µm o.d.) coated with hydroxypropyl cellulose was 
initially filled a background electrophoresis buffer of 0.1 M acetic acid at pH 2.8. The 
sample containing saliva protein digests was prepared in a 2% pharmalyte solution. A 
50 cm long sample plug, corresponding to 4.0 µl of sample volume, was injected into 
the capillary by pressure. A positive electric voltage of 24 kV was then applied to the 
inlet reservoir, which was filled with a 0.1 M acetic acid solution.  
UV absorbance detection at 214 nm was placed at 14 cm from the cathodic end of the 
capillary. The cathodic end of the capillary was housed inside a stainless steel needle 
using a coaxial liquid sheath flow configuration69. A sheath liquid composed of 0.1 M 
acetic acid was delivered by using a Harvard Apparatus 22 syringe pump (South 
Natick, MA). The stacked and resolved peptides in the CITP capillary were 
sequentially fractionated and loaded into individual wells on a moving microtiter 
plate.    
To couple transient CITP/CZE with nano-RPLC, peptides collected in individual 
wells were sequentially injected into individual trap columns (3 cm x 200 µm i.d. x 
365 µm o.d.) packed with 5 µm porous C18 reversed-phase particles. Each peptide 




quaternary pump (Dionex, Sunnyvale, CA) and a dual nano-flow splitter connected to 
two pulled-tip fused-silica capillaries (50 μm i.d. x 365 μm o.d.). These two 15-cm 
long capillaries were packed with 3-µm Zorbax Stable Bond (Agilent, Palo Alto, CA) 
C18 particles.  
Nano-RPLC separations were performed in parallel in which a dual-quaternary pump 
delivered two identical 2-hr organic solvent gradients with an offset of 1 hr. Peptides 
were eluted at a flow rate of 200 nL/min using a 5-45% linear acetonitrile gradient 
over 100 min with the remaining 20 min for column regeneration and equilibration. 
The peptide eluants were monitored using a linear ion-trap mass spectrometer (LTQ, 
ThermoFinnigan, San Jose, CA) operated in a data dependent mode. Full scans were 
collected from 400 - 1400 m/z and 5 data dependent MS/MS scans were collected 
with dynamic exclusion set to 30 sec. A moving stage housing two nano-RPLC 
columns was employed to provide electrical contacts for applying ESI voltages, and 
most importantly to position the columns in-line with the ESI inlet at each 
chromatography separation and data acquisition cycle. 
 
2.2.4  Data Analysis 
Raw LTQ data were converted to peak list files by msn_extract.exe 
(ThermoFinnigan). Open Mass Spectrometry Search Algorithm (OMSSA)19 was used 
to search the peak list files against a decoyed SwissProt human database. This 
database was constructed by reversing all 12,484 real sequences and appending them 
to the end of the sequence library. Searches were performed by setting up the 




fragment ion mass tolerance, 1 missed cleavage, alkylated Cys as a fixed modification 
and variable modification of Met oxidation. Follow-up searches were also performed 
using semi-tryptic and no enzyme specificities without variable modifications. 
Searches were run in parallel on a 12 node, 24 CPU Linux cluster (Linux Networx, 
Bluffdale, UT).  
FDRs were determined using the method of Elias and co-workers70. Briefly, FDRs 
were calculated by multiplying the number of false positive identifications (hits to the 
reversed sequences scoring below a given threshold) by 2 and dividing by the number 
of total identifications. Peptides occurring as matches to the forward sequences were 
not counted as false positives. A curve was then generated by plotting FDR versus E-
value and an E-value threshold corresponding to a 1% FDR for total peptide 
identifications was used as the cutoff in this study. OMSSA E-value is the expectation 
value that a tandem MS event represents the predicted peptide given a number of 
factors, including the quality of the match between the experimental and theoretical 
fragment ion spectra, the search space as determined by the sequence library, the 
precursor and fragment ion mass accuracy settings, enzyme specificity, and missed 
cleavages and modifications19. 
   
2.3  Result and Discussion 
2.3.1  Optimization of Transient CITP/CZE Separations 
One of key issues in performing CE separations involves the elimination of 
protein/peptide adsorption onto the capillary wall. The adsorption of proteins and 




analyte band broadening. Application of polyacrylamide coating as described in our 
previous CIEF work18 produced satisfactory performance in both the separation 
efficiency and the resolving power. However, the polyacrylamide coating has limited 
column life at acidic pH and the entire coating procedure is quite time consuming. 
Thus, the use of hydroxypropyl cellulose71 as the capillary coating was evaluated and 
demonstrated for the simplicity in the coating protocol, the robustness in the multiple 
usage, and the superior performance in the elimination of electroosmotic pumping 
and protein/peptide adsorption.   
For the separation of cationic analytes at acidic pHs, ammonium acetate has been 
reported as the most common leading electrolyte used in the CITP process7, 66-68. In 
contrast to the generation of a pH gradient in CIEF, carrier ampholytes such as 
commercially available pharmalyte 3-10, which exhibit high electrophoretic 
mobilities, were also investigated as the potential candidate for the leading electrolyte 
employed in transient CITP/CZE separations. By comparing with the use of 
ammonium acetate, pharmalyte ions not only offered lower electric currents to avoid 
the joule heating during the separation, but also greatly enhanced the solubility of 
stacked proteins and peptides.   
It is also interesting to note that the final concentration of the analyte in CITP is 
independent from the applied electric voltage. However, the application of low electric 
field strengths would lead to poorer resolution among the stacked zones and longer 
migration time in CITP7, 66-68. We have determined to routinely apply an electric field 
strength of 300 V/cm across the entire capillary in order to reduce the joule heating while 




Due to the limitation of a 30-kV high-voltage power supply available in our laboratory, a 
80-cm long coated capillary was typically employed for performing transient CITP/CZE 
separations. The inner diameter of coated capillary was chosen from initial 50 μm to 100 
μm in order to increase the sample loading by a four-fold. However, the joule heating, 
which also increases with increasing the inner diameter, prevented the use of even larger 
capillary columns in transient CITP/CZE.  
Furthermore, the use of formic acid has been reported to greatly improve the solubility of 
hydrophobic proteins and peptides72, 73. Besides the use of acetic acid, formic acid was 
also employed as the terminating electrolyte in the background electrophoresis buffer and 
investigated for its effect on transient CITP-CZE separations while enhancing analyte 
solubility in the stacked zones. However, there was no apparent enhancement in the 
solubility of protein digests associated with the use of formic acid as the terminating 
electrolyte. The presence of pharmalyte ions as the leading electrolyte may already 
provide sufficient enhancement in peptide solubility.    
By comparing with CIEF, CITP offers a broader field of application, particularly for 
protein separation and concentration. Proteins with extreme pI values may be outside the 
working pH range of CIEF due to limited availability of commercial ampholytes for the 
creation of a pH gradient inside the capillary. Furthermore, proteins focused in CIEF 
reside at their pIs where they have an increased tendency to precipitate. In contrast, the 
stacked proteins in CITP are less prone to precipitation due to their charged nature.  
2.3.2  Analysis of Saliva Sample by CITP-Based Proteome Technology 
An important aspect of any multidimensional proteome separation platform is its ability to 




protein/peptide mixtures. As opposed to universally enriching all proteins by a similar 
degree in most sample concentration techniques, the CITP stacking process specifically 
targets trace amounts of proteins7, 66-68 and thus reduces the range of relative protein 
abundances for providing unparallel advantages towards the identification of low 
abundance proteins. Such selective proteome enrichment enabled by the CITP process can 
be represented by the Kohlrausch equation68: 
                                 CA  =  CL/{[µL/(µL + µR)] [(µA + µR)/ µA]}           (1) 
Where CA is the analyte concentration in the stacked zone; CL is the molarity of the 
leading electrolyte; and µ is the electrophoretic mobility (the subscript R refers to the 
counter ion). It can be concluded that the final concentration of the analyte, CA, is largely 
proportional to the molarity of the leading buffer, CL. Depending on the initial 
concentrations of individual sample components relative to the molarity of the leading 
buffer, the result of the CITP stacking process is that major compounds may be diluted, 
but trace peptides are concentrated.  
As a selective enrichment technique, it is also interesting to note that the final 
concentration of the analyte in CITP is independent from the applied electric voltage. 
However, the application of low electric field strengths would lead to poorer resolution 
among the stacked zones and longer migration time in CITP7, 66-68. In order to obtain 
excellent separation resolution in CITP, the operational electrolyte system should be 
optimized to give appropriate differences among the effective mobilities of analytes. As 
the pH and ionic strength of the stacked zones in CITP are different from each other, 




Thus, on-column transition of CITP to CZE was employed as the first separation 
dimension in this study to combine selective analyte enrichment with improved zone 
resolution. Two important requirements7, 66 were fulfilled in order to induce transient 
CITP/CZE separation of complex proteome mixtures. The mobility of the co-ion of the 
background electrolyte (0.1 M acetic acid at pH 2.8) was lower than the sample 
components (tryptic digest of human salivary proteins) during the transient CITP step so 
that it served as the terminating ion. The proteome sample also contained an additional co-
ion (2% pharmalyte)74, 75 with high electrophoretic mobility as the leading electrolyte. 
Under the influence of applied electric field, the higher mobility pharmalyte ions rushed to 
the frontal boundary of the sample zone and sample stacked between the high-mobility 
leading electrolyte and the low-mobility terminating electrolyte in the background 
electrophoresis buffer. Once the leading electrolyte has migrated away, and the peptides 
were completely stacked, transient CITP was followed by CZE of concentrated peptides in 
the background electrolyte. 
In addition to a transient CITP/CZE-UV trace, the number of distinct peptides identified 
from each of the CITP/CZE fractions is summarized in Figure 2-1. In all, 24 peptide 
fractions were sampled from the first dimension of transient CITP/CZE separation with a 
total peptide loading of only 8.0 µg (injected volume of 4.0 µL x peptide concentration of 
2.0 µg/µL).  
Each peptide fraction was further resolved by the second dimension nano-RPLC 
separation and the eluants were detected using ESI-tandem MS. As shown in Figure 2-2, 
the peptide and protein FDRs and the numbers of total peptides, distinct peptides, and 




OMSSA E-value is the expectation value that a tandem MS event  represents the predicted 
peptide given a number of factors, including the quality of the match between the 
experimental and theoretical fragment ion spectra, the search space as determined by the 
sequence library, the precursor and fragment ion mass accuracy settings, enzyme 
specificity, and missed cleavages and modifications. An E-value threshold of 0.003, 
corresponding to 1% FDR of total peptide identifications, was chosen as the cutoff in this 
study and led to the identification of 6,112 fully tryptic peptides covering 1,479 distinct 
human SwissProt protein entries. This cutoff led to a protein FDR of 8.8% as indicated by 
the detection of peptides from 66 distinct reversed protein sequences in the decoy section 
of the search database. 
By increasing the number of CIEF fractions from 29 in our previous study65 to 54 in 
this work, a total of 4,589 fully tryptic peptides were sequenced at a 1% FDR of total 
peptide hits, leading to the identification of 1,374 distinct SwissProt protein entries 
from the same saliva sample. By increasing the number of CIEF fractions in 
combined CIEF/nano-RPLC separations, the numbers of distinct peptides and protein 
identifications were clearly higher than those (3,642 fully tryptic peptides and 1,165 
distinct proteins) reported previously65. Even though only 24 transient CITP/CZE 
fractions were taken in this study (Figure 2-1), the CITP-based multidimensional 
separation platform, equipped with selective analyte enrichment, yielded the largest 
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Figure 2-1 Overlaid plots containing the transient CITP/CZE-UV trace monitored at 













Figure 2-2 Plots of the FDRs and the numbers of total peptide, distinct peptide, and 
distinct protein identifications versus the E-value obtained from the search 














2.3.3  Comparison of CITP- and CIEF-Based Proteome Technology 
By comparing with the CIEF-based proteome technology14, 17, 18, transient CITP/CZE 
separations offer a broader field of application. Peptides with extreme pI values may be 
outside the working pH range of CIEF due to limited availability of commercial 
ampholytes for the creation of a pH gradient inside the capillary. Furthermore, analytes 
focused in CIEF reside at their pIs where they have an increased tendency to precipitate. 
In contrast, the stacked peptides in CITP are less prone to precipitation due to their 
charged nature.  
As shown in Figure 2-3, the proteome results obtained from combined transient 
CITP/nano-RPLC separations are further compared with those achieved using 54 CIEF 
fractions. A total of 1,121 human saliva proteins were identified by both the CITP- and 
CIEF-based multidimensional separation platforms coupled with ESI-tandem MS, 
corresponding to greater than 81% protein overlapping. Small proteins with a molecular 
mass of less than 20 kDa constitute a characteristic portion of the human saliva proteome. 
A total of 361 small proteins were identified by combining the results attained from both 
the CITP and CIEF proteome platforms. A number of these small proteins are PRPs which 
are involved in creating a protective film over teeth and promoting remineralization of the 
enamel. Additionally, several antimicrobial proteins are also identified including β-
defensin 125 precursor, β-defensin 1 precursor, FALL-39 precursor, mucins 5B and 2, 6 










Figure 2-3 Venn diagrams comparing the saliva proteome results obtained from the 





















The ultrahigh resolving power of transient CITP/CZE is evidenced by the large number of 
distinct peptide identifications measured from each CITP fraction (Figure 2-1) with even 
lower peptide fraction overlapping than that typically observed in the CIEF separation 
(Figure 2-4). In this case, approximately 85% of distinct peptides were identified in only a 
single CITP fraction. Of the remaining peptides, 8% were identified in two fractions and 
7% were measured in three and more fractions. In comparison with the multidimensional 
liquid chromatography system55, 64, a high degree of peptide overlapping in the first 
dimension of strong cation exchange chromatography unnecessarily burdens the 
subsequent separation and greatly reduces the overall peak capacity in a multidimensional 
separation system. The presence of high abundance peptides in multiple chromatography 
fractions negatively impacts the selection of low abundance peptides for tandem MS 
identification. Additionally, the poor resolution of low abundance peptides adversely 
affects their final concentrations in the eluting peaks prior to the ESI-MS analysis. 
When evaluating the protein sequence coverage by the number of distinct peptides 
mapping to each protein identification, CITP similarly achieves the best performance 
with 674 proteins (46%) having 3 or more distinct peptides, 288 (19%) having 2 
distinct peptides, and 517 (35%) having a single distinct peptide (Figure 2-5). The 
CIEF-based multidimensional separation returns 38% of proteins with 3 or more 
distinct peptides, 20% with 2 distinct peptides, and 42% with single peptide hits. 
Another measure of proteome data quality includes the ratio of total peptide to 
distinct protein identifications which are 17.19 (25,428 total peptides/1,479 distinct 




CIEF-based proteome platforms, respectively. This ratio becomes increasingly 
important when implementing the spectral counting-based protein quantification 
approach76, as the expression levels of each protein are determined by the number of 
tandem MS events.   
As demonstrated by the common observation in the literature, most false peptide 
identification tend to be ones in which the corresponding proteins is only identified 
by a single peptides. Thus, many proteomic research laboratories routinely discard 
single-peptide identifications to significantly reduce the FDR of distinct protein 
identifications. However, as pointed out by the work of Elias and Gygi 77, these 
single-protein identifications after filtering are mostly correct and typically represent 
30-50% of a proteome data set. The removal of these protein identifications greatly 
and negatively impacts the coverage and the sensitivity of overall proteome analysis. 
As advocated by Elias and Gygi 77 and also implemented in this study, the target-
decoy search strategy is employed as the routine practice to design more stringent 
criteria for single-peptide identifications. 
Due to selective analyte enrichment of transient CITP/CZE separations, there is also a 
higher proportion of signaling proteins, including kinases, identified by the CITP-
based proteome technology. Representative kinases including cAMP-dependent 
protein kinase type II-α regulatory subunit (P13861), heat-shock protein β-8 
(Q9UJY1), and hexokinase type III (P52790) are presented in Figure 2-6 together 

































































































Figure 2-4 The percentage of distinct peptides identified from single or multiple CITP 
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Figure 2-5 The number of distinct proteins identified by single or multiple distinct 


















Figure 2-6 Tandem MS spectra of distinct peptide hits contributing to the 
identification of representative kinases including (A) cAMP-dependent 
protein kinase type II-α regulatory subunit, (B) heat-shock protein β-8, and 
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2.4  Conclusion 
There is a growing interest in using saliva as a diagnostic fluid due to its relatively 
simple and minimally invasive collection procedures. However, as with any body 
fluids, the saliva proteome exhibits a large variation of protein relative abundances 
including high abundance proteins such as amylases, mucins, PRPs, and secretory 
IgA complex. This work presented our continuous efforts toward the identification 
and cataloging of salivary secretory components using combined CITP/nano-RPLC 
separations coupled with ESI-tandem MS. Compared with CIEF utilized as the first 
separation dimension in our previous studies17, 18, 65, transient CITP/CZE not only 
contributed to selective analyte enrichment toward low abundance proteins, but also 
provided high resolving power for addressing the complexity of the saliva proteome. 
The ultrahigh resolving power of transient CITP/CZE is evidenced by the large 
number of distinct peptide identifications measured from each CITP fraction together 
with the low peptide fraction overlapping among identified peptides.   
A total of 6,112 fully tryptic peptides were detected at a 1% FDR, leading to the 
identification of 1,479 distinct SwissProt protein entries from a single human saliva 
sample. A hit rate (total peptide identifications over tandem MS queries) of 0.11 was 
achieved over approximately 232,600 MS2 queries in a single CITP-based proteome 
measurement. The remaining 89% of queries included noise, contaminants, non-
peptide biological components, post-translational modifications that were not 
searched, peptides with cleavage events that were not searched, and, frequently, fully 
tryptic peptides that were below the accepted threshold for identification. It has been 




considered correct78. Furthermore, it has been suggested that the application of 
ultrahigh mass accuracy and resolution from a linear ion trap-Orbitrap hybrid mass 
spectrometer may allow the elimination of virtually any false positive peptide 
identifications79. An as yet largely unexplored option for improving peptide search 
sensitivity is the use of spectral matching80, 81, in which the tandem MS spectral 
signature of a high quality peptide hit is used as the reference comparison during the 
search, rather than a predicted fragmentation pattern. This spectral matching 
technique has long been utilized in the field of gas chromatography-MS and is widely 
accepted for the classification of small molecules.  
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3.1  Introduction 
Mitochondria have a variety of essential responsibilities in cellular metabolism, e.g. the 
production of ATP through oxidative phosphorylation in aerobic cells as well as the 
initiation of the signal cascade leading to apoptosis 82. Alteration of the mitochondrial 
proteome and altered mitochondrial function has been implicated in a variety of 
degenerative diseases, heart disease, aging, and cancer 83-85. Because the mitochondria are 
a major source of endogenously generated reactive oxygen species (ROS), it is not 
surprising that they have been proposed to play a major role in aging 86, 87. The free radical 
theory of aging predicts that oxidative damage to the mitochondria can lead to an 
amplifying effect whereby damaged mitochondria release more ROS, further increasing 
oxidative damage 88. The accumulation of damaged mitochondria results in a decrease in 




damage exceeds the capacity of the cell to handle removal of both ROS and oxidatively 
damaged macromolecules 89. 
In addition to their biological and medical significance, mitochondria are ideal targets for 
global proteome analysis because they have a manageable level of complexity as a 
consequence of their apparent prokaryotic ancestry. Their endosymbiotic origins have 
been preserved in their double membrane structure, and they possess their own circular 
genome with mitochondria-specific transcription, translation, and protein assembly 
systems. Mammalian mitochondria DNA encodes for 13 essential polypeptide 
components of the oxidative phosphorylation system, small and large rRNAs, and 22 
tRNAs. The remaining mitochondrial proteins of the oxidative phosphorylation system, 
metabolic enzymes, membrane channel proteins, and any other proteins regulating 
mitochondrial function are derived from the nuclear genome. Import of these proteins into 
the mitochondria is highly regulated through the function of protein chaperones and the 
inner and outer transmembrane peptide import complexes 90, 91. However, the coordination 
of protein synthesis from two separate genomes within a cell and their correct 
submitochondrial assembly is not fully understood 92. 
While two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) has been 
employed toward an inventory of the mitochondrial proteome 89, 93-98, mitochondria 
contain many membrane-bound and very basic proteins that are quite difficult to be 
analyzed by 2-D PAGE 92, 94. Consequently, considerable efforts have been devoted to the 
application of various liquid chromatography (LC) techniques in single or 
multidimensional separation format prior to mass spectrometry (MS) detection for the 




studies fully exploit the resolution and sensitivity achievable with multidimensional LC-
MS or sodium dodecyl sulfate (SDS)-PAGE/LC-MS approaches, allowing many 
additional mitochondrial proteins to be identified.  
Still, proteins cataloged from reported proteomic studies comprise only small part of 
the estimated 1,500 111, 112 and 697-4,532 113 total human mitochondrial proteins. The 
actual number of mitochondrial proteins is difficult to determine as these estimations 
can have a false discovery rate (FDR) of up to 68% 113. Even with reduced protein 
complexity in the subcellular proteome, the goal of achieving comprehensive 
proteome analysis is still challenged by the large variation of protein relative 
abundances. A capillary isotachophoresis (CITP)-based multidimensional separation 
platform, capable of providing selective analyte enrichment 7, 66-68, 114 and high 
resolving power toward complex protein/peptide mixtures, is therefore employed in 
this study for the analysis of synaptic mitochondria isolated from the brains of mice.       
3.2  Experimental Section 
3.2.1  Material and Reagents 
Fused-silica capillaries (50 µm i.d./375 µm o.d. and 100 µm i.d./375 µm o.d.) were 
acquired from Polymicro Technologies (Phoenix, AZ). Acetic acid, bovine serum albumin 
(BSA), dithiothreitol (DTT), ethylene glycol tetraacetic acid (EGTA), N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), iodoacetamide (IAM), 
mannitol, and sucrose were obtained from Sigma (St. Louis, MO). Acetonitrile, 
hydroxypropyl cellulose (average MW 100,000), SDS, 




(Pittsburgh, PA). Pharmalyte 3-10 and Percoll were acquired from Amersham Biosciences 
(Piscataway, NJ). Sequencing grade trypsin was obtained from Promega (Madison, WI). 
All solutions were prepared using water purified by a Nanopure II system (Dubuque, IA) 
and further filtered with a 0.22 µm membrane (Millipore, Billerica, MA). 
3.2.2  Isolation of Synaptic Mouse Brain Mitochondria 
Animal experiments were performed in accordance with the Guide for the Care and Use 
of Laboratory Animals and approved by the University of Maryland Institutional Animal 
Care and Use Committee. Male (20 g) wild-type C57BL/6 mice were used. Mice were 
decapitated, and brains were removed and homogenized in ice-cold isolation medium 
containing 225 mM mannitol, 75 mM sucrose, 5 mM HEPES, and 1 mM EGTA, pH 7.4, 
at 4 0C. As described previously 115, a slightly modified procedure by Dunkely et al. 116 
was employed to separate synaptosomes and nonsynaptic mitochondria. Briefly, after low-
speed spin (1300 g for 3 min) of the brain homogenate, the supernatant was centrifuged at 
21,000 g for 10 min. The pellet was suspended in 3% Percoll and layered on top of a 
preformed gradient of 24% (3.5 mL), 15% (2 mL), 10% (1.5 mL) of Percoll and 
centrifuged at 32,000 g for 8 min. Nonsynaptic mitochondria sedimented at the bottom of 
the tube and the synaptosomes accumulated at the interface of 24 and 15% Percoll and 
also at the interface of 15 and 10% Percoll.  
The synaptosomes were collected and the mitochondria were released from synaptosomes 
using a nitrogen cavitation technique 117, 118. The suspension was layered onto a preformed 
gradient of 40% (1.5 mL) and 24% (3.5 mL) Percoll. The mitochondria accumulated at 
the interface of 40 and 24% Percoll gradient. After the mitochondria fraction was collected 




mitochondria. Synaptic mitochondria were suspended in isolation medium containing 1 
mg/mL BSA to remove free fatty acid from mitochondrial membranes. The purity of 
synaptosome and mitochondria isolated from the Percoll gradient was examined with 
electron microscopy and demonstrated in our previous studies 115-118.  
 
3.2.3  Mitochondrial Sample Preparation 
After centrifugation at 7,500 g, the mitochondrial pellet was suspended and treated 
with a solution containing 1% SDS, 50 mM Tris (pH 8.0), and 1 mM DTT. After 
centrifugation at 20,000 g for 30 min, the supernatant was collected as the SDS-
solubilized mitochondrial proteins. The SDS-solubilized mitochondrial proteins were 
placed in a dialysis cup and dialyzed overnight at 4 0C against 100 mM Tris at pH 8.0. 
The dialyzed proteins were denatured, reduced, and alkylated by sequentially adding 
urea, DTT, and IAM with final concentrations of 8 M, 1 mg/mL, and 2 mg/mL, 
respectively. The solution was incubated at 37 0C for 1 hr in the dark and then diluted 
8-fold with 100 mM ammonium acetate at pH 8.0. Trypsin was added at a 1:40 (w/w) 
enzyme to substrate ratio and the solution was incubated at 37 0C overnight. Tryptic 
digests were desalted using a Peptide MacroTrap column (Michrom Bioresources, 
Auburn, CA), lyophilized to dryness using a SpeedVac (Thermo, San Jose, CA), and 
then stored at -80 0C. Approximately 100 - 300 μg of mitochondrial proteins were 




3.2.4  Transient CITP/Capillary Zone Electrophoresis (CZE)-Based 
Multidimensional Separations 
The CITP apparatus was constructed in-house using a CZE 1000R high-voltage 
power supply (Spellman High-Voltage Electronics, Plainview, NY). A 80-cm long 
CITP capillary (100 μm i.d./365 μm o.d.) coated with hydroxypropyl cellulose was 
initially filled a background electrophoresis buffer of 0.1 M acetic acid at pH 2.8. The 
sample containing mitochondrial protein digests was prepared in a 2% pharmalyte 
solution and was hydrodynamically injected into the capillary. A positive electric 
voltage of 24 kV was then applied to the inlet reservoir, which was filled with a 0.1 
M acetic acid solution.  
UV absorbance detection at 214 nm was placed at 14 cm from the cathodic end of the 
capillary. The cathodic end of the capillary was housed inside a stainless steel needle 
using a coaxial liquid sheath flow configuration 69. A sheath liquid composed of 0.1 
M acetic acid was delivered by using a Harvard Apparatus 22 syringe pump (South 
Natick, MA). The stacked and resolved peptides in the CITP/CZE capillary were 
sequentially fractionated and loaded into individual wells on a moving microtiter 
plate.     
To couple transient CITP/CZE with nano-reversed phase liquid chromatography 
(nano-RPLC), peptides collected in individual wells were sequentially injected into 
individual trap columns (3 cm x 200 μm i.d. x 365 μm o.d.) packed with 5 μm porous 
C18 particles. Each peptide fraction was subsequently analyzed by nano-RPLC 
equipped with an Ultimate dual-quaternary pump (Dionex, Sunnyvale, CA) and a 




x 365 µm o.d.). These two 15-cm long capillaries were packed with 3-μm Zorbax 
Stable Bond (Agilent, Palo Alto, CA) C18 particles.  
Nano-RPLC separations were performed in parallel in which a dual-quaternary pump 
delivered two identical 2-hr organic solvent gradients with an offset of 1 hr. Peptides 
were eluted at a flow rate of 200 nL/min using a 5-45% linear acetonitrile gradient 
over 100 min with the remaining 20 min for column regeneration and equilibration. 
The peptide eluants were monitored using a linear ion-trap mass spectrometer (LTQ, 
ThermoFinnigan, San Jose, CA) operated in a data dependent mode. Full scans were 
collected from 400 - 1400 m/z and 5 data dependent MS/MS scans were collected 
with dynamic exclusion set to 30 sec. A moving stage housing two nano-RPLC 
columns was employed to provide electrical contacts for applying ESI voltages, and 
most importantly to position the columns in-line with the ESI inlet at each 
chromatography separation and data acquisition cycle.   
 
3.2.5  Data Analysis 
Raw LTQ data were converted to peak list files by msn_extract.exe 
(ThermoFinnigan). OMSSA 19 was used to search the peak list files against a decoyed 
Mus musculus subset of the UniProt sequence library (April 20, 2006). This database 
was constructed by reversing all 41,178 sequences and appending them to the end of 
the sequence library. Searches were performed using the following parameters: fully 
tryptic, 1.5 Da precursor ion mass tolerance, 0.4 Da fragment ion mass tolerance, 1 




Met oxidation. Searches were run in parallel on a 12 node, 24 CPU Linux cluster 
(Linux Networx, Bluffdale, UT).  
FDRs were determined using the method of Elias and co-workers 70. Briefly, FDRs 
were calculated by multiplying the number of false positive identifications (hits to the 
reversed sequences scoring below a given threshold) by 2 and dividing by the number 
of total identifications. Similar to those described and discussed in our previous work 
119, an E-value threshold corresponding to a 1% FDR for total peptide identifications 
was used as the cutoff in this study.  
 
 
3.3  Result and Discussion 
While CITP has been widely used for analyte preconcentration prior to electrophoretic 
separation 66-68, the application of CITP to selectively enrich trace amounts of 
proteins/peptides in complex mixtures presents an untapped strategy for maximizing 
proteome coverage. As demonstrated in our recent studies 7, 114, such selective 
enhancement toward low abundance proteins can drastically reduce the range of relative 
protein abundances and greatly improve the sequence analysis of low abundance proteins 
in complex proteomes such as human saliva proteome 114. Furthermore, on-column 
transition of CITP to CZE was employed in this study in order to optimize selective 
analyte enrichment while achieving excellent separation resolution.   
To induce transient CITP/CZE separation 7, 66, the mobility of the co-ion of the 
background electrolyte (0.1 M acetic acid at pH 2.8) was lower than the sample 
components (tryptic digest of  mitochondrial proteins) during the transient CITP step so 




ion (2% pharmalyte) 74, 75 with high electrophoretic mobility as the leading electrolyte. 
Under the influence of applied electric field, the higher mobility pharmalyte ions rushed to 
the frontal boundary of the sample zone and sample stacked between the leading and 
terminating electrolytes. Transient CITP was followed by CZE of concentrated peptides in 
the background electrolyte. Stacked peptides were resolved in CZE based on their 
differences in electrophoretic mobility. 
A representative transient CITP/CZE-UV trace is shown in Figure 3-1. In all, 20 
peptide fractions were sampled from the first dimension of the transient CITP/CZE 
separation with a total peptide loading of only 15 μg (injected sample volume of 4.0 
μL x peptide concentration of  3.75 μg/μL). Each peptide fraction was further 
resolved by nano-RPLC as the second separation dimension and the chromatography 
eluants were analyzed using ESI-tandem MS. By using a target-decoy search strategy 
70, 119, an E-value threshold of 0.0013, corresponding to 1% FDR of total peptide 
identifications, was chosen as the cutoff in this study and led to the identification of 
12,110 fully tryptic peptides covering 1,795 distinct mouse SwissProt protein entries.  
In this study, tandem MS spectra were searched against a decoyed Mus musculus 
subset of the UniProt sequence library (April 20, 2006). The UniProt sequence library 
consists of entries from both SwissProt and TrEMBL. Only protein hits mapping to 
the SwissProt subset are reported here in order to reduce the redundancy of the 
protein search results. To highlight the relatively low degree of protein redundancy in 
the SwissProt database employed in this study, these 1,795 distinct mouse protein 











































Figure 3-1 Overlaid plots containing the transient CITP/CZE-UV trace monitored at 














In addition to a representative transient CITP/CZE-UV trace, Figure 3-1 also 
summarizes the number of distinct peptides identified from each of the 20 CITP/CZE 
fractions. The ultrahigh resolving power of transient CITP/CZE is clearly 
demonstrated by the large number of distinct peptide identifications measured from 
each CITP fraction together with significantly low peptide fraction overlapping 
shown in Figure 3-2. For the analysis of tryptic peptides of mitochondrial proteins, 
approximately 78% of distinct peptides were identified in only a single CITP fraction. 
Of the remaining peptides, 15% were identified in two fractions and 7% were 
measured in three and more fractions.  
As shown in Figure 3-2, the degree of peptide overlapping among CITP fractions is even 
lower than that achieved using combined capillary isoelectric focusing (CIEF)/nano-
RPLC separations 14, 17, 18, 65 for the analysis of the same mitochondrial sample. As 
observed in our previous studies 14, 17, 18, 65, the isoelectric point (pI) of basic peptides may 
not be well defined and the basic peptides do not focus as tightly as those of acidic 
counterparts during the CIEF separation. In comparison with the shotgun-based 
multidimensional LC system 55, 64, a high degree of peptide overlapping was typically 
observed with 40-80% of carry over peptides that were identified in previous salt steps in 





































































Figure 3-2 The degree of peptide overlapping among CITP/CZE or CIEF fractions 











When evaluating the protein sequence coverage by the number of distinct peptides 
mapping to each mitochondrial protein identification, CITP/CZE similarly achieved 
superior performance with 1,041 proteins (58%) having 3 or more distinct peptides, 
233 (13%) having 2 distinct peptides, and 521 (29%) having a single distinct peptide. 
The CIEF-based mitochondrial proteome analysis returned 53% of proteins with 3 or 
more distinct peptides, 16% with 2 distinct peptides, and 31% with single peptide hits. 
Another measure of proteome data quality includes the ratio of total peptide hits to 
distinct protein identifications which were 22.4 (40,116 total peptide hits/1,795 
distinct protein) for the CITP/CZE-based proteome platform. This ratio becomes 
increasingly important when implementing the spectral counting-based protein 
quantification approach 76, as the expression levels of each protein are determined by 
the number of tandem MS events.  
As reported by the common observation in the literature, most false peptide 
identifications tend to be ones in which the corresponding protein is only identified 
by a single peptide. Thus, many proteomic research laboratories routinely discard 
single peptide identifications to significantly reduce the FDR of distinct protein 
identifications. However, as pointed out by the work of Elias and Gygi’s 77 and our 
laboratories 119, these single-protein identifications after filtering are mostly correct 
and often represent 30-50% of a proteome data set. The removal of these protein 
identifications greatly and negatively impacts the coverage and the sensitivity of 
overall proteome analysis. As advocated by Elias and Gygi 77 and also implemented 
in this study, the target-decoy search strategy is employed as the routine practice to 




The same protein digest obtained from synaptic mouse brain mitochondria was repeatedly 
analyzed by both the CITP/CZE and CIEF-based multidimensional separation platforms 
equipped with ESI-tandem MS. The percentage of overlapping proteins obtained from 
repeated CITP/CZE-nano-RPLC runs was around 86% as illustrated by the Venn diagram 
shown in Figure 3-3A. A total of 2,095 distinct mouse SwissProt protein entries (or 1,992 
non-redundant proteins) were identified from combined CITP/CZE-nano-RPLC runs of a 
single mouse brain mitochondria sample. On the other hand, the repeated CIEF-nano-
RPLC proteomic studies returned a total of 1,543 distinct protein identifications (or 1,465 
non-redundant proteins) with greater than 87% of protein overlapping among replicates 
(Figure 3-3B). As shown in Figure 3-3C, more than 93% of CIEF-cataloged 
mitochondrial proteins were inclusive in the results of the CITP/CZE proteomic studies. 
There were 96 and 648 proteins uniquely identified by the CIEF and CITP/CZE-based 
proteomic platforms, respectively. 
Due to the use of electrokinetic migration/mobilization of charged analytes in transient 
CITP/CZE, the collected CITP fractions for subsequent nano-RPLC separations are less 
prone to contamination such as non-ionic surfactants or polymers employed during 
various sample storage and preparation processes. Significant enhancement in the overall 
peak capacity of the CITP-based proteomic platform can be realized by increasing the 
number of CITP fractions. The intrinsic high resolution of transient CITP-CZE allows the 
number of fractions sampled in the first separation dimension to be further increased by 















Figure 3-3 Venn diagrams comparing the mouse mitochondrial proteome results 
obtained from repeated (A) CITP/CZE and (B) CIEF analyses. (C) 
Comparing the combined proteomic results obtained from repeated 






The excellent reproducibility of transient CITP-CZE together with straightforward CITP 
fractionation using a robust sheath liquid interface 69 enables user discretion as to the 
number of fractions to be gathered and analyzed, and which interesting fractions may be 
revisited (reanalyzed) or repeatedly accumulated for identification of extremely low 
abundance peptides and proteins.  
Combined proteomic results obtained from two CITP/CZE-nano-RPLC runs of a 
single mouse brain mitochondria sample (Figure 3-3A) were compared to the 
mitochondrial protein reference set predicted by Maestro 113. By using a threshold 
score of 4.69 (corresponding to a 10% FDR), the Maestro reference set contained a 
list of 1,207 mouse mitochondrial proteins. Among these 1,207 proteins, a total of 
198 proteins were no longer listed in the updated UniProt sequence library (April 20, 
2006) and were subtracted from the reference dataset. Combined CITP/CZE analyses 
covered 59% (598 proteins) and 41% (413 proteins) of the updated Maestro 
mitochondrial reference set on the basis of proteins identified by a single and at least 
two distinct peptides, respectively.  
In contrast, only 178 out 1,075 mouse brain mitochondrial proteins identified by 
Kislinger et al. 108 overlapped with the updated Maestro mitochondrial reference set, 
corresponding to less than 18% coverage. Besides significant increase in the coverage 
of the Maestro reference set, the ratios of mitochondrial proteins (included in Maestro) 
to total protein identifications in our proteomic results ranged from 0.26 (413/1,571) 
to 0.29 (598/2,095) on the basis of proteins identified by a single and at least two 
distinct peptides, respectively. These ratios were again higher than 0.16 (178/1075) 




The combined CITP/CZE and CIEF dataset was compared to the mitochondrial 
protein reference set of the MitoP2-database 120 containing a list of 731 mouse 
mitochondrial proteins.  553 out 2,191 distinct proteins (or 2,082 non-redundant 
proteins) presented in this study overlapped with the MitoP2-database, corresponding 
to 76% mouse mitochondrial proteome coverage. On the other hand, approximately 
45% of the proteins identified by Forner and colleagues 109 (a total of 887 proteins 
collected from rat tissues of muscle, heart, and liver) had an apparent orthologue 
against the 2004 mouse MitoP database 121. The proteomic results of mouse brain 
mitochondria achieved by Kislinger et al. 108 were also compared to the mitochondrial 
protein reference set of the MitoP2-database. Only 146 out 1,075 cataloged proteins 
overlapped with the MitoP2-database, corresponding to less than 20% coverage. It is 
interesting to note that the entirety of these 146 proteins and 90% of proteins 
collected from the work of Kislinger et al. 108 were included in the combined 
CITP/CZE and CIEF dataset.  
By employing the mitochondrial proteome dataset obtained from combined 
CITP/CZE and CIEF analyses, the top 17 biosynthetic and metabolic pathways were 
mapped out by the Ingenuity Pathway AnalysisTM and are shown in Figure 3-4. The 
ratio is calculated as the number of proteins in a given pathway which meet cutoff 
criteria divided by total number of proteins which make up that pathway. The 
significance value associated with the functional analysis for a dataset is a measure 
for how likely the proteins from the dataset under investigation participate in that 
function. The significance is expressed as a p-value, which is calculated using the 




of user-specified proteins of interest that participate in a given function or pathway, 
relative to the total number of occurrences of these proteins in all functional/pathway 
annotations stored in the Ingenuity Pathway Knowledge Base. 
The most significant metabolic pathway revealed by our mitochondrial dataset is 
clearly the oxidative phosphorylation pathway. As energy producers to sustain the 
living cell activities, mitochondria constantly convert the glycolysis products, 
pyruvate and NADH, into energy in the form of ATP through the cellular respiration 
process. In order to generate ATP in the efficient way, mitochondria require 
numerous transport proteins and enzymes to perform the oxidation reactions of the 
respiratory chain, the ATP synthesis, and the regulations of metabolites and substance 
transportations.  
A total of 100 proteins engaged in the oxidative phosphorylation pathway, 
corresponding to approximately 62% pathway coverage, were identified in this study. 
Five complexes involved in the oxidative phosphorylation pathway were shown in 
Figure 3-5, including NADH dehydrogenase, fumarate reductase, cytochrome bc1 
complex, cytochrome c oxidase, and ATP synthase families. The coverage of 
different complexes were analyzed as 87% (40/46) for complex I, 80% (4/5) for 
complex II, 73% (8/11) for complex III, 85% (11/13) for complex IV, and 94% 
(15/16) for complex V. The overall complex coverage was around 86% (78/91) and 
higher than 62% pathway coverage. As shown in Figure 3-6, tandem MS spectra of 
single unique peptide hits leading to the identifications of NDUA1, NU3M, and 
NU4LM as representative subunits of complex I exhibited excellent E-values of 5.8 x 








Figure3- 4 Top 17 biosynthetic and metabolic pathways constructed from combined 
mitochondrial proteome dataset using the Ingenuity Pathway AnalysisTM. The 
significance and the ratio of the proteome dataset associated with individual 














Figure 3-5 Simplified illustration of the oxidative phosphorylation pathway containing 










































































































































































































































































































































































































































































































































































































































































































































Figure 3-6 Tandem MS spectra of single unique peptide hits leading to the identifications 




3.4  Conclusion 
Mitochondria are a major source and target of free radicals 83-85, 94, 122, 123, and the collapse 
of the mitochondrial transmembrane potential can initiate the signaling cascades involved 
in programmed cell death or apoptosis 82, 124-126. Mitochondria play a crucial role in the 
regeneration of antioxidants through the production of reducing equivalents 127, and are 
responsible for the vast majority of ATP production within most cells and higher 
organisms. Mitochondria also infer a major role in cell signaling, as well as biosynthesis 
(e.g. heme) and degradation (e.g. urea cycle) 128. Mitochondrial mutations and dysfunction 
have been implicated in numerous diseases including aging, cancer, heart disease, 
neurological diseases such as Parkinson, Alzheimer, and Huntington, and various 
neuromuscular syndromes 122, 129-131. The mitochondrial connection to these major 
degenerative diseases has consequently driven significant research efforts to define the 
mitochondrial proteome and to discover new molecular targets for drug development and 
therapeutic intervention. 
The work presented in this study highlights our continuous efforts toward the development 
and characterization of electrokinetic-based proteome technologies for mining deeper into 
complex proteomes such as the mouse mitochondria proteome. Transient CITP/CZE not 
only contributed to selective enrichment of low abundance peptides/proteins 7, 114, but also 
resolved peptides/proteins based on their differences in electrophoretic mobility. The 
ultrahigh resolving power of transient CITP/CZE was evidenced by the large number of 
distinct peptide identifications measured from each CITP/CZE fraction and the low 
peptide fraction overlapping among identified peptides.  In addition to selective analyte 




separations greatly increased the number of detected peptides and proteins identified due 
to better use of the MS dynamic range and reduced discrimination during ionization. 
A total of 12,110 fully tryptic peptides were detected at a 1% FDR, leading to the 
identification of 1,795 distinct mouse SwissProt protein entries (or 1,705 non-
redundant proteins) from a single CITP/CZE-based proteomic study of synaptic 
mouse brain mitochondria. The reproducibility of protein identifications was 
evaluated and was found to be around 86% by comparing proteins identified from 
repeated runs of the same mitochondrial sample. The analysis of the mouse 
mitochondrial proteome by two CITP/CZE runs led to the detection of 2,095 distinct 
protein entries (or 1,992 non-redundant proteins), corresponding to 59% coverage of 
the updated Maestro mitochondrial reference set. By combining the results obtained 
from the CITP/CZE and CIEF-based proteomic studies, the collective analysis 
yielded the identification of 2,191 distinct protein entries (or 2,082 non-redundant 
proteins), corresponding to 76% coverage of the MitoP2-database reference set. The 
increased coverage of mouse mitochondrial proteome further revealed the top 17 
biosynthetic and metabolic pathways in synaptic mitochondria isolated from mouse 
brain using the Ingenuity Pathway AnalysisTM.  
3.5  Acknowledgement 
I would like to acknowledge Drs. Weijie Wang  and Li Yang for helping trouble 
shooting in LC-MS, Drs. Krish Chandrasekaran and Tibor Kristian for providing 
mouse mitochondria samples, and Drs. Brian M. Balgley and Cheng S. Lee for 






Chapter 4:  Comparison of Multidimensional Shotgun 
Technologies Targeting Tissue Proteomics 
Reproduced with permission from Fang, X., Park, D.M., Lee, C. S., Balgley, B. M., 
Submitted to Nat. Methods. 
  
4.1  Introduction 
Although blood is the preferred assay specimen for a final diagnostic test, the biological 
materials analyzed for biomarker discovery need not be plasma. In addition to the 
analytical challenges posed by the complexity and depth of the plasma proteome, many 
biomarkers elaborated from diseased tissues as the result of leakage and secretion are 
massively diluted into circulating blood with ultimate concentrations which are five to 
seven orders of magnitude lower in abundance than the most highly concentrated plasma 
proteins. If biomarkers specific for a particular disease arise locally from the affected 
tissue, it is highly plausible that a gradient of concentration diminishes with increasing 
distance from the site of disease. Thus, it has been proposed that a better way to discover 
biomarkers might be to study tissues involved in disease or the fluids bathing theses 
tissues132, 133. 
However, in the absence of protein amplification, proteomic analysis of tumor specimens 
is severely constrained by sample amounts ranging from 103-105 cells, corresponding to a 
total protein content of 0.1-10 µg23. While surface-enhanced laser desorption/ionization-




as few as 25-50 cells4, 134, the transition from spectral patterns produced by SELDI-MS to 
protein identity is generally quite difficult135. The inherent large-scale and the difficulty of 
this protein identification process not only account for both the small number of proteins 
identified and the tendency toward the identification of highly abundant proteins, but also 
call into question the practicality of the overall SELDI-MS approach when working with 
limited clinical samples. 
While two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) analyses of tissue 
samples have been attempted24, 136-143, including the analysis of minute tumor tissues25, 144-
147, these studies required significant manual effort and time to extract sufficient levels of 
protein for analysis, while providing little information on protein expression beyond a 
relatively small number of high abundance proteins. On the other hand, the reported tissue 
proteomic studies employing multidimensional liquid chromatography separations148-151 
have been mainly based on the analysis of entire tissue sections instead of targeted cell 
populations. The minimal quantity of available protein samples from limited cell 
populations has restricted recent analyses152-160 to the use of only a single chromatography 
separation prior to tandem MS analysis and greatly limited the ability for mining deeper 
into the tissue proteome.  
Combined capillary isoelectric focusing (CIEF)/nano-reversed phase liquid 
chromatography (nano-RPLC) separations coupled with electrospray ionization-mass 
spectrometry (ESI-MS) have been demonstrated to enable ultrasensitive analysis of 
minute proteins extracted from fresh-frozen14, 16, 17 and formalin-fixed and paraffin-
embedded (FFPE) tissues21, 22. As evaluated in our recent analyses of human saliva 




based proteomic platform not only enables selective enrichment of low abundance 
proteins, but also provides superior resolving power than that achieved using 
CIEF/nano-RPLC separations. In this work, comparisons among shotgun proteome 
technologies, including multidimensional CITP and liquid chromatography 
separations54, 55, 162, are performed regarding their abilities to address the challenges 
of protein complexity and relative abundance inherent in cancer stem cells as a model 
tissue proteome system. 
 
4.2  Experimental Section 
4.2.1  Materials and Reagents 
Fused-silica capillaries (50 µm i.d./375 µm o.d. and 100 µm i.d./375 µm o.d.) were 
acquired from Polymicro Technologies (Phoenix, AZ). Acetic acid, dithiothreitol (DTT), 
iodoacetamide (IAM), and trifluoroacetic acid (TFA) were purchased from Sigma (St. 
Louis, MO). Acetonitrile, ammonium acetate, ammonium formate, hydroxypropyl 
cellulose (average MW 100,000), sodium dodecyl sulfate (SDS), 
tris(hydroxymethyl)aminomethane (Tris), and urea were obtained from Fisher Scientific 
(Pittsburgh, PA). Pharmalyte 3-10 was purchased from Amersham Pharmacia Biotech 
(Uppsala, Sweden). Sequencing grade trypsin was acquired from Promega (Madison, WI). 
All solutions were prepared using water purified by a Neu-Ion system (Baltimore, MD) 





4.2.2  Preparation of Glioblastoma Derived Cancer Stem Cells 
Neural stem cells were isolated from glioblastoma multiforme (GBM) tissues and 
cultured163 in Dr. Deric M. Park’s laboratory at the University of Pittsburgh Cancer 
Institute. Pelleted cells were suspended in a buffer that consisted of 50 mM Tris (pH 
8.0), 65 mM DTT, and 10% glycerol. The cells were disrupted by homogenization 
with glass beads in a Mini-BeadBeater (BioSpec Products, Bartlesville, OK). The 
soluble proteins were collected in the supernatant by centrifugation at 20,000 g for 30 
min.  
Proteins collected in the supernatant were denatured, reduced, and alkylated by 
sequentially adding urea, DTT, and IAM with final concentrations of 8 M, 1 mg/mL, 
and 2 mg/mL, respectively. The solution was incubated at 37 0C for 1 hr in the dark 
and then diluted 8-fold with 100 mM ammonium acetate at pH 8.0. Trypsin was 
added at a 1:40 (w/w) enzyme to substrate ratio and the solution was incubated at 37 
0C overnight. Tryptic digests were desalted using a Peptide MacroTrap column 
(Michrom Bioresources, Auburn, CA), lyophilized to dryness using a SpeedVac 
(Thermo, San Jose, CA), and then stored at -80 0C. 
 
4.2.3  Transient CITP/Capillary Zone Electrophoresis (CZE)-Based 
Multidimensional Separations 
Transient CITP/Capillary Zone Electrophoresis (CZE)-Based Multidimensional 
Separations. Similar to the procedures described in our previous studies114, 161, a 80-
cm long CITP capillary (100 μm i.d./365 μm o.d.) coated with hydroxypropyl 




acid at pH 2.8. The samples containing protein digests processed from neural stem 
cells were prepared in a 2% pharmalyte solution. A 50-cm long sample plug, 
corresponding to 4.0 μL sample volume, was hydrodynamically injected into the 
capillary. A positive electric voltage of 24 kV was then applied to the inlet reservoir 
filled with a 0.1 M acetic acid solution.   
The cathodic end of the capillary was housed inside a stainless steel needle using a 
coaxial liquid sheath flow configuration164, 165. A sheath liquid composed of 0.1 M 
acetic acid was delivered by using a Harvard Apparatus 22 syringe pump (South 
Natick, MA). The stacked and resolved peptides in the CITP/CZE capillary were 
sequentially fractionated and loaded into individual wells on a moving microtiter 
plate.  
Peptides collected in individual wells were sequentially injected into dual trap 
columns (3 cm x 200 μm i.d. x 365 μm o.d.) packed with 5 μm porous C18 reversed-
phase particles. Each peptide fraction was subsequently analyzed by nano-RPLC 
equipped with an Ultimate dual-quaternary pump (Dionex, Sunnyvale, CA) and a 
dual nano-flow splitter connected to two pulled-tip fused-silica capillaries (50 μm i.d. 
x 365 μm o.d.). These two 15-cm long capillaries were packed with 3-μm Zorbax 
Stable Bond (Agilent, Palo Alto, CA) C18 particles.  
Nano-RPLC separations were performed in parallel in which a dual-quaternary pump 
delivered two identical 2-hr organic solvent gradients with an offset of 1 hr. Peptides 
were eluted at a flow rate of 200 nL/min using a 5-45% linear acetonitrile gradient 
over 100 min with the remaining 20 min for column regeneration and equilibration. 




ThermoFinnigan, San Jose, CA) equipped with an electrospray ionization interface 
and operated in a data dependent mode. Full scans were collected from 400 - 1400 
m/z and 5 data dependent MS/MS scans were collected with dynamic exclusion set to 
30 sec. 
 
4.2.4 Strong Cation-Exchange (SCX) Coupled with Nano-RPLC-ESI-MS 
A SCX column (5 cm length x 300 µm i.d.) packed with 5-µm poly(2-sulfoethyl 
aspartamide) particles were purchased from PolyLC (Columbia, MD). The salt gradient 
for SCX was the same as that employed by Liu and co-workers for the characterization of 
the human plasma proteome166. Briefly, peptides were eluted at a flow rate of 10 µL/min 
using a 10-255 mM ammonium formate gradient (containing 25% acetonitrile) over 50 
min with the remaining 20 min for column regeneration and equilibration. Peptides 
collected in individual wells of a microtiter plate were lyophilized to dryness and 
reconstituted in a 0.1% TFA solution containing 2% acetonitrile. Peptide fractions 
resolved from SCX were subsequently and individually analyzed using nano-RPLC-ESI-
MS by following the same procedures described previously.  
  
 
4.2.5  MS Data Analysis 
Raw LTQ data were converted to peak list files by msn_extract.exe 
(ThermoFinnigan). Open Mass Spectrometry Search Algorithm (OMSSA)19 




the peak list files against the UniProt sequence library (April 20, 2006) with decoyed 
sequences appended. This decoyed database was constructed by reversing all 
sequences and appending them to the end of the sequence library. Searches were 
performed using the following parameters: fully tryptic, 1.5 Da precursor ion mass 
tolerance, 0.4 Da fragment ion mass tolerance, 1 missed cleavage, alkylated Cys as a 
fixed modification and variable modification of Met oxidation. Searches were run in 
parallel on a 12 node, 24 CPU Linux cluster (Linux Networx, Bluffdale, UT).  
False discovery rates (FDRs) were determined using a target-decoy search strategy 
introduced by Elias and co-workers70 and employed in our previous study for a 
comparative evaluation among commonly used tandem MS identification search 
algorithms119. Briefly, FDRs were calculated by multiplying the number of false 
positive identifications (hits to the reversed sequences scoring below a given 
threshold) by 2 and dividing by the number of total identifications. Peptides identified 
below threshold, and also occurring as matches to the forward sequences, were not 
counted as false positives or true identifications. A curve was then generated by 
plotting E-value versus FDR and an E-value threshold corresponding to a 1% FDR 
for total peptide identifications was chosen as a cutoff in this study. The UniProt 
sequence library consists of entries from both SwissProt and TrEMBL. Only peptide 











4.3  Result and Discussion 
4.3.1  Evaluation of overall proteome performance 
Increasing evidence support the hypothesis that a variety of cancers, including GBM, 
the most common and malignant brain tumor, arise from malignant transformation of 
undifferentiated stem-progenitor cells. Similar to normal neural stem cell (multipotent 
cells in the central nervous system capable of differentiating into neurons, astrocytes, 
and oligodendrocytes), GBM derived stem cells express primitive markers, self-
renew, and are able to differentiate to multiple lineages upon activation of appropriate 
pathways167, 168. The presence of malignant stem-like cells within the heterogeneous 
cell populations in GBM is thought to be responsible for recurrence, infiltration into 
surrounding white matter, and radiation-chemoresistance. Therefore, treatment 
strategies directed against the malignant stem cell compartment of GBM has the 
potential to limit proliferation and invasion to allow a greater tumor resection, and 
more durable response to radiation and chemotherapy. 
Neural stem cells were isolated from GBM tissues and cultured163 in Dr. Park’s 
laboratory as part of ongoing research collaboration toward the identification of stem 
and differentiation markers in determining cellular behavior, including growth, 
motility, proliferative index, and survival. Similar to primary cell cultures, 
glioblastoma derived cancer stem cells in culture have a very limited lifespan before 
they senesce. Thus, these small cancer stem cell populations isolated from tumor 
tissues and enriched in culture represent an excellent opportunity for conducting 




including transient CITP/CZE-based multidimensional separations and 
multidimensional protein identification technology (MudPIT)54, 55, 162. 
Comparisons were achieved using a single processed tryptic digest of cancer stem 
cells, equal loading of 15 μg digest into the CITP capillary and the SCX column, 
same nano-RPLC-ESI-MS conditions, and identical search parameters together with a 
consistent cutoff as established by the target-decoy determined FDR70, 119. By 
enhancing the overall separation peak capacity and the MS duty cycle, the numbers of 
total spectral counts (or total peptide identifications), distinct peptides, and distinct 
proteins summarized in Figure 4-1 all increased with increasing the number of SCX 
fractions from 4, 8, and 30. A 30 CITP/CZE-fraction measurement, however, resulted 
in further enhancements in total peptide, distinct peptide, and distinct protein 
identifications over a 30-fraction SCX run by 119%, 192%, and 79%, respectively.    
There were very good agreements between proteomic results obtained from 30 
fractions SCX- and CITP-based shotgun techniques on a core set of proteins 
identified by at least one (Figure 4-2A) or two (Figure 4-2B) distinct peptides. The 
Venn diagrams illustrated that the CITP-based proteomic platform uniquely detected 
2,614 proteins by one or more distinct peptides or 1,524 proteins by two or more 
distinct peptides. Proteins identified by two or more distinct peptides using MudPIT 
were completely included in the CITP measurements. In addition to increasing the 
number of protein identifications, the percentage of proteins identified by two or 
more distinct peptides also increased from 60% (19% + 41%) in 4- and 8-fraction 




percentage was further increased to 77% using transient CITP/CZE-based 
multidimensional separations.  
Other measures of proteome data quality are the average numbers of spectral counts 
and distinct peptide identifications per protein. Increase in the number of distinct 
peptide identifications per protein is interpreted as an improvement in the confidence 
and the sequence coverage of a protein identification169. The number of spectral 
counts becomes very important when implementing spectral counting-based label-
free quantification76, 170, 171, as the expression levels of each protein are determined by 
the number of tandem MS events. Although CITP delivered 79% more protein 
identifications (Figure 4-1), CITP still outperformed MudPIT with respect to both 
measures: an average of 18.8 spectral counts and 6.9 distinct peptides per protein in 
CITP versus an average 15.4 spectral counts and 4.3 distinct peptides of each protein 
in MudPIT. 
4.3.2  Comparison of separation performance 
The high resolving power of transient CITP/CZE as the first separation dimension is 
clearly demonstrated by significantly low peptide fraction overlapping shown in Figure 4-
4. Approximately 89% of distinct peptides were identified in only a single CITP fraction. 
Of the remaining peptides, 8% were identified in two fractions and 3% were measured in 
three and more fractions. Only a 4-fraction MudPIT run exhibited lower fraction 










Figure 4-1 Summary of proteomic results of GBM derived neural stem cells using 














Figure 4-2 The Venn diagrams comparing proteins detected using MudPIT (small 
cycle) and CITP/CZE-based multidimensional separations (large cycle). 









Figure 4-3 Summary of the percentages of proteins identified by one, two, or more 












Figure 4-4 Summary of the percentages of peptides identified from single or multiple 
CITP and SCX fractions using MudPIT and CITP/CZE-based 










The percentage of distinct peptides identified in only a single SCX fraction decreased 
from 94% in 4 fractions to 80% in 8 fractions and 61% in 30 fractions. In contrast, 
this percentage determined from the CITP measurements was only reduced from 95% 
in 15 fractions to 89% in 30 fractions. Thus, the intrinsically high resolution of 
transient CITP/CZE allows the number of fractions sampled in the first separation 
dimension to be increased for enhancing the overall peak capacity of 
multidimensional separations and the resulting proteome coverage, particularly for 
the characterization of small cell populations and limited tissue samples. 
While increasing the number of CITP fractions, the amount of individual (not total) 
peptides collected in each of CITP fractions and subsequently loaded into each of 
nano-RPLC columns still remained the same as long as there was no over-sampling. 
By maintaining the same amount of individual peptides introduced and resolved in 
nano-RPLC-MS, the enhancement in the overall peak capacity further reduced matrix 
effects by simplifying the complexity of co-eluting peptides prior to MS detection and 
sequencing. Matrix effects negatively affect the dynamic range and detection 
sensitivity of MS measurements in three critical ways. First, high abundance peptides 
compete for ionization and leave less current available for low abundance peptides. 
Second, the presence of highly abundant ions limits the opportunity of low abundance 
ions for entering the ion trap and being selected for tandem MS sequencing. Last, the 
MS detector itself has a finite dynamic range and can be saturated by the presence of 
higher abundance ions. 
In addition to analyzing fraction overlapping, the ratio of new distinct peptides 




all prior fractions was also evaluated and summarized in Figure 4-5. Extensive 
fraction overlapping in SCX clearly limits its ability to identify new peptides. 
Comparisons among 4-, 8-, and 30-fraction SCX runs indicated that the new peptide 
ratio reached a maximum around the salt concentration of 110-130 mM ammonium 
formate, corresponding to the elution of mainly triply charged peptides. The 
association of this maximum new peptide ratio with 3+ charged peptides was also in 
good agreement with the highest number of peptide identifications achieved from 
triply charged peptides in the work of Peng and co-workers 162.  
In contrast, the CITP-based multidimensional separations delivered high new peptide 
ratios evenly across all 30 fractions. Transient CITP/CZE separations resolve peptides 
due to their differences in electrophoretic mobility which is influenced by the charge 
and size of the peptide ions, and provides better selectivity over charge-based SCX. It 
is known that capillary electrophoresis, in general, offers superior separation 
efficiency than that typically achieved in LC, further contributing to enhancement in 
the overall resolving power.  
 
4.3.3  Assessment of proteome reproducibility 
The CITP-based proteomic platform was coupled with the spectral counting quantification 
approach76, 170, 171 for determining protein expression profile within GBM derived cancer 
stem cells. The spectral counts of individual proteins were normalized against the average 
number of spectral counts across all runs and termed expression values. Several measures, 
including the coefficient of variation (CV) and the Pearson correlation coefficient, were 
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Figure 4-5 The ratio of new distinct peptides found in each SCX or CITP fraction 











Correlation of two runs of the same tryptic digest of neural stem cells is shown in 
Figure 4-6. All separations were performed on different CITP capillaries and nano-
RPLC columns. All proteins with one or more spectral counts were used to calculate 
the correlation yielding a Pearson R2 value of 0.98 over a dynamic range of greater 
than 103. This value compares favorably with a recent report of a Pearson R2 
correlation of 0.88 among technical replicates using MuDPIT172. Furthermore, the CV 
was less than 10% for over half of proteins quantified and averaged 15% across all 
proteins. 
 
4.3.4  Protein functional subclass and pathway coverage 
The Venn diagrams shown in Figure 4-7 specifically compare the proteome coverage 
among various functional categories, including tyrosine kinases, kinases, 
transmembrane, proto-oncogenes, apoptosis, and transcription regulators, achieved 
using the CITP-based proteomic platform and MudPIT. The CITP measurements 
routinely detected about two fold more proteins in any given subclass, even for very 
low abundance proteins such as tyrosine kinases and proto-oncogenes. Similar to 
comparative proteome results shown in Figure 4-2, very few proteins in these 
subclasses were uniquely identified by MudPIT. 
The approach of grouping individual expression changes into pathways of actions is 
not only useful in trying to interpret genomic and proteomic datasets, but also allows 



















Figure 4-6 Pearson correlation plot of all proteins quantified in two runs of the same 










Figure4-7 The Venn diagrams comparing proteins identified within different 
functional categories using MudPIT (small cycle) and CITP/CZE-based 












Comparative proteomics involving measurements in changes of biological pathways 
or functions are expected to provide relevant therapy-associated biomarkers and 
networks, and the initial steps and control points in signaling cascades and 
compensatory processes that drive the progression of therapeutic response and/or 
drug resistance. From a practical perspective, the evaluation of comparative 
proteomic dataset within a biological context is essential for high-throughput data 
validation, prioritization of follow-on biomarker selection and validation experiments. 
The coverage of key protein networks related to neural cancer stem cells such as the 
extracellular signal regulated kinases (ERK)/mitogen-activated protein kinases 
(MAPK) pathway (Figure 4-8) was analyzed using the Ingenuity SystemTM and 
compared among the results achieved by the CITP proteomic platform and MudPIT. 
Clearly, combined CITP/nano-RPLC separations, due to its excellent resolving power, 
accomplished significantly greater coverage in this key pathway than that obtained 
from the multidimensional liquid chromatography system. Many biologically relevant 
proteins, including MKP, Rafs, and Src in the ERK/MAPK pathway, were only 










Figure 4-8 Comparison of the coverage in the ERK/MAPK pathway achieved by 
MudPIT and CITP/CZE-based shotgun proteome techniques. Red: 
proteins only identified by CITP; blue: proteins identified by CITP with 
higher confidence (larger numbers of spectral counts and distinct peptide 
identifications per protein) than that achieved by MudPIT; green: proteins 






4.4  Conclusion 
Since the sizes of human tissue biopsies are becoming significantly smaller due to the 
advent of minimally-invasive methods and early detection and treatment of lesions, a 
more effective discovery-based proteomic technology is critically needed to enable 
comprehensive and sensitive studies of protein profiles that will have diagnostic and 
therapeutic relevance. By employing small cancer stem cell populations isolated from 
GBM tissues and enriched in culture, comparisons among shotgun proteome 
techniques, including transient CITP/CZE-based multidimensional separations and 
MudPIT, were performed and reported in this work. Comparisons were conducted 
using a single processed protein digest with equal sample loading, identical second 
dimension separation and MS conditions, and consistent search parameters and cutoff 
established by the target-decoy determined FDR.   
For the evaluation of overall proteome performance, a CITP/CZE measurement 
demonstrated significant enhancements in total peptide, distinct peptide, and distinct 
protein identifications over a corresponding SCX run by 119%, 192%, and 79%, 
respectively. On the basis of at least two or more distinct peptides leading to each 
protein identification, the Venn diagram indicated the complete inclusion of proteins 
identified by MudPIT within the CITP-based proteomic results. CITP further 
outperformed MudPIT with respect to the average numbers of distinct peptide 
identifications and spectral counts per protein which lead to improvements in the 
sequence coverage and the confidence of protein quantification. 
As evaluated by the measurements of CV and the Pearson correlation coefficient, the 




demonstrated to be highly sensitive and reproducible in determining protein relative 
abundance in complex tissue proteome. In contrast, extensive fraction overlapping in 
SCX greatly limited the ability of MudPIT for mining deeper into the tissue proteome. 
As evidenced by the coverage among various protein functional categories, CITP 
routinely detected about two fold more proteins in any given subclass, even for very 
low abundance proteins such as tyrosine kinases and proto-oncogenes. Combined 
CITP/nano-RPLC separations, due to its excellent resolving power, further 
accomplished superior coverage in key pathways than that of MudPIT. Many 
biologically relevant proteins, including MKP, Rafs, and Src in the ERK/MAPK 
pathway, were only identified by the CITP-based shotgun proteomic measurements.   
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Chapter 5:  Conclusion 
The ability to perform comparative proteome analysis, including the changes in 
protein expression and post-translational modifications, would have profound impact 
on our understanding of how disease occurs and develops, and provide a molecular 
basis for future drug intervention to treat human diseases. Besides protein complexity, 
the greatest bioanalytical challenge facing comprehensive proteome analysis of 
clinical specimens, particularly in the identification of low abundance proteins, is 
related to the large variation of protein relative abundances (>6 orders of magnitude). 
One obvious approach to increase the detection capability of low abundant proteins is 
to significantly raise the sample loading along with many additional protein/peptide 
fractionation and separation procedures, and therefore is impractical for proteomic 
studies of small cell populations and limited tissue samples.  
Thus, this project aims to demonstrate the application of a CITP-based 
multidimensional separation platform, capable of providing selective analyte 
enrichment and extremely high resolving power toward complex protein/peptide 
mixtures, to achieve comprehensive proteome analysis including the characterization 
of low abundance proteins. In contrast to universally enriching all analytes by a 
similar degree, the result of the CITP stacking process is that major components may 
be diluted, but trace compounds are concentrated. Such selective enhancement toward 
low abundance proteins drastically reduces the range of relative protein abundances 
within complex proteomes, and greatly enhances proteomic coverage using the CITP-
based proteomic technology. Furthermore, CITP offers the benefits of speed and 




transient CITP/CZE. Transient CITP/CZE further provides seamless combination 
with nano-RPLC as two highly resolving and completely orthogonal separation 
techniques in an integrated platform. 
5.1  Summary of Accomplishments 
Chapter 2 presents our continuous efforts toward the development and application of 
electrokinetics-based proteome technologies for mining deeper into the human saliva 
proteome. Compared with CIEF utilized as the first separation dimension in our 
previous studies, transient CITP/CZE not only contributes to selective analyte 
enrichment toward low abundance proteins, but also provides high resolving power 
for addressing the complexity of the saliva proteome. The ultrahigh resolving power 
of transient CITP/CZE is evidenced by the large number of distinct peptide 
identifications measured from each CITP fraction together with the low peptide 
fraction overlapping among identified peptides.  A total of 6,112 fully tryptic peptides 
are detected at a 1% FDR, leading to the identification of 1,479 distinct human 
SwissProt protein entries from a single human saliva sample.  
Mitochondria are a major source and target of free radicals, and the collapse of the 
mitochondrial transmembrane potential can initiate the signaling cascades involved in 
programmed cell death or apoptosis. Mitochondria play a crucial role in the regeneration 
of antioxidants through the production of reducing equivalents, and are responsible for the 
vast majority of ATP production within most cells and higher organisms. Mitochondrial 
mutations and dysfunction have been implicated in numerous diseases including aging, 
cancer, heart disease, neurological diseases such as Parkinson, Alzheimer, and Huntington, 




degenerative diseases has consequently driven significant research efforts to define the 
mitochondrial proteome and to discover new molecular targets for drug development and 
therapeutic intervention. 
As presented in Chapter 3, selective analyte enrichment together with total peak capacity 
improvements in combined CITP/CZE-nano-RPLC separations greatly increase the 
number of detected peptides and proteins identified from synaptic mitochondria isolated 
from mouse brain due to better use of the MS dynamic range and reduced discrimination 
during ionization. A total of 12,110 fully tryptic peptides are detected at a 1% FDR, 
leading to the identification of 1,795 distinct mouse SwissProt protein entries from a 
single CITP/CZE-based proteomic study of synaptic mouse brain mitochondria. The 
reproducibility of protein identifications is found to be around 86% by comparing proteins 
identified from repeated runs of the same mitochondrial sample. The analysis of the 
mouse mitochondrial proteome by two CITP/CZE runs leads to the detection of 2,095 
distinct protein entries, corresponding to 59% coverage of the updated Maestro 
mitochondrial reference set. By combining the results obtained from the CITP/CZE and 
CIEF-based proteomic studies, the collective analysis yields the identification of 2,191 
distinct protein entries, corresponding to 76% coverage of the MitoP2-database reference 
set. The increased coverage of mouse mitochondrial proteome further reveals the top 17 
biosynthetic and metabolic pathways in synaptic mitochondria isolated from mouse brain 
using the Ingenuity Pathway AnalysisTM.  
Since the sizes of human tissue biopsies are becoming significantly smaller due to the 
advent of minimally-invasive methods and early detection and treatment of lesions, a 




comprehensive and sensitive studies of protein profiles that will have diagnostic and 
therapeutic relevance. By employing small cancer stem cell populations isolated from 
GBM tissues and enriched in culture, comparisons among shotgun proteome 
techniques, including transient CITP/CZE-based multidimensional separations and 
MuDPIT, are performed and reported in Chapter 4. Comparisons are conducted using 
a single processed protein digest with equal sample loading, identical second 
dimension separation and MS conditions, and consistent search parameters and cutoff 
established by the target-decoy determined FDR.   
For the evaluation of overall proteome performance, a CITP/CZE measurement 
demonstrates significant enhancements in total peptide, distinct peptide, and distinct 
protein identifications over a corresponding SCX run by 119%, 192%, and 79%, 
respectively. On the basis of at least two or more distinct peptides leading to each 
protein identification, the Venn diagram indicates the complete inclusion of proteins 
identified by MudPIT within the CITP-based proteomic results. CITP further 
outperforms MudPIT with respect to the average numbers of distinct peptide 
identifications and spectral counts per protein which lead to improvements in the 
sequence coverage and the confidence of protein quantification. 
As evaluated by the measurements of CV and the Pearson correlation coefficient, the 
CITP-based proteome platform coupled with the spectral counting approach is 
demonstrated to be highly sensitive and reproducible in determining protein relative 
abundance in complex tissue proteome. In contrast, extensive fraction overlapping in SCX 
greatly limited the ability of MudPIT for mining deeper into the tissue proteome. As 




detected about two fold more proteins in any given subclass, even for very low abundance 
proteins such as tyrosine kinases and proto-oncogenes. 
 
5.2  Contributions to Current Proteomic Technologies Development 
By comparing with CIEF, CITP offers a broader field of application. Peptides with 
extreme pI values may be outside the working pH range of CIEF due to limited 
availability of commercial ampholytes for the creation of a pH gradient inside the capillary. 
Furthermore, analytes focused in CIEF reside at their pIs where they have an increased 
tendency to precipitate. In contrast, the stacked peptides in CITP are less prone to 
precipitation due to their charged nature. Most importantly, the ultrahigh resolving power 
of CITP/CZE is evidenced by the large number of distinct peptide identifications 
measured from each CITP fraction together with the low peptide fraction overlapping 
among identified peptides.  
The intrinsic high resolution of transient CITP/CZE allows the number of fractions 
sampled in the first separation dimension to be further increased by simply increasing the 
number of deposits collected in a microtiter plate. The excellent reproducibility together 
with straightforward CITP fractionation enables user discretion as to the number of 
fractions to be gathered and analyzed, and which interesting fractions may be revisited 
(reanalyzed) or repeatedly accumulated for identification of extremely low abundance 
peptides. In comparison with a multidimensional liquid chromatography system such as 
MudPIT, an increase in the number of the SCX fractions only contributes to minor 




5.3  Future Work 
The proteome measurement system’s dynamic range is defined as the ratio of the quantity 
of a protein of high abundance to the quantity of a protein of low abundance. The 
maximum dynamic range for a single mass spectrum without the use of spectrum 
averaging or summation is typically constrained to about 1,000. The use of 
multidimensional chromatography platforms in shotgun proteomics has resulted in better 
utilization of the MS dynamic range and reduced discrimination among analytes during 
ionization, thus achieving a system’s dynamic range of 10,000:1. One part of my proposed 
future studies will involve the determination of the overall dynamic range of the CITP-
based proteomic technology using complex protein digests spiked with isotopically 
labeled peptides of known concentrations. These peptides will be synthesized and labeled 
with stable isotopes using Sigma’s custom services. Additionally, the results of 
quantitative immunoassays, provided by Rules-Based Medicine 
(www.rulesbasedmedicine.com), will also be employed to evaluate the dynamic range of 
proteins identified by combined CITP-CZE/nano-RPLC separations equipped with ESI-
LTQ-MS/MS.  
Besides the use of Western Blot and immunohistochemistry techniques for validating 
individual protein biomarkers, another part of my proposed future studies will be 
centered on the application of an absolute quantification (AQUA)-LC-single reaction 
monitoring (SRM) approach.  Peptides which are diagnostic for the candidate marker 
proteins based on discovery results obtained from the CITP-based proteomic studies 
will be synthesized and labeled with stable isotopes using Sigma’s custom services. 




and serve as internal standards. AQUA peptides will be synthesized to contain at least 
a 6 Da shift utilizing 13C to avoid isotopic interference with the native peptide and to 
ensure identical elution time with the native peptide in nano-RPLC.  
Optimal collision energy levels will be determined independently for each AQUA 
peptide by nano-electrospray infusion of the peptide. The ratio of peak areas from a 
pair of labeled and non-labeled peptides of the same sequence permits a 
determination of the absolute quantity of the unlabeled peptide based on the known 
quantity of the AQUA peptide. Both labeled and label-free peptides will fragment in 
exactly the same manner, providing further verification of the peptide sequence. 
AQUA-LC-SRM permits the analysis of hundreds of candidate peptide ions in a 
single nano-RPLC run, allowing for broad-based, sensitive validation of the initial 
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